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Abstract
People with psychotic disorders have long-term negative health outcomes and contribute
large health system costs. Intervening among those at ultra-high risk (UHR) for psychosis
may prevent or mitigate risk for psychotic disorder; however, it is unclear if we should
treat all UHR individuals or only those above a certain risk threshold. The objectives
were to systematically review the literature on the cost-effectiveness of UHR programs,
and to conduct an economic evaluation of a risk stratification strategy, where treatment
decisions are based on the probability of transitioning to psychotic disorder. Our
systematic review found that UHR programs are potentially cost-effective. The economic
evaluation found that only treating those at ≥20% risk to transition is cost saving to the
Canadian health system, but returns worse health outcomes ($15,466 per quality-adjusted
life-year), relative to treating all UHR individuals. Future research requires better
valuation of cost and outcomes and trials examining risk stratification.
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Summary for Lay Audience
Psychotic disorders are mental illnesses that have long-term negative consequences for a
person’s functioning and quality of life, and are often expensive to treat and manage.
Some studies have found that treating people at high risk for psychosis in specialized
programs may be effective for slowing down progression to psychosis or preventing it
entirely. Little is known about the cost-effectiveness of high risk programs compared to
alternative treatment plans. Therefore, it is important to examine the cost-effectiveness of
treating people in high risk programs to help inform future health policy decisions related
to this population. The aim of this thesis was to review all available studies on the costeffectiveness of high risk programs, and to then use this knowledge to inform the creation
of an economic model to evaluate the potential benefit of prioritizing treatment to those at
a much higher risk for psychosis (≥20% risk). In our review of prior economic studies
comparing high risk programs to standard care, we found that high risk programs may
provide value for money, but no conclusions can be drawn on what aspects of the
treatment plan are cost-effective. Next, an economic evaluation was done to assess the
Canadian health care system costs of only treating those at a very high risk for converting
to psychosis (≥20% risk) based on a risk calculator compared to a standard ‘treat all’
strategy. Risk stratification has incremental costs of $15,466 to the health system per
quality-adjusted life-year, compared to the other strategy. More specifically, our results
show that risk stratification has potential to provide cost savings, but returns worse
outcomes. This means that cost savings can occur only if health system decision-makers
are willing to accept losses in health. Future economic evaluations would benefit from
more rigorous methods of examining health care outcomes and costs associated with high
risk programs. Future clinical trials that compare the effectiveness of personalized
treatment plans to the standard of care may also help inform future economic models.
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Chapter 1
1
Introduction
1.1
Overview
An episode of psychosis occurs when a person cannot adequately distinguish between
what is and is not reality.2 It is characterized by the presence of positive symptoms – such
as delusions, hallucinations, and disorganized thought and behavior patterns – but may
also include negative symptoms, such as diminished facial expressions, loss of
motivation, and minimized speech.2 Psychotic episodes may occur in the context of a
number of mental disorders diagnosed using the Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition (DSM-5),3 but most commonly occur in schizophrenia
spectrum disorders.4,5 Observational studies indicate that psychotic disorders are often
comorbid with other mental illnesses, such as substance use disorders and depression.6
Psychotic disorders contribute to the global burden of disease by increasing the risk of
long-term disability, negative health outcomes, and premature mortality.6–9 Psychotic
disorders are also responsible for substantial economic costs. The most recent metaanalysis found the pooled worldwide incidence of psychotic disorders to be
approximately 26.6 cases per 100 000 person-years (95% CI 22.0–31.7).10 Psychotic
disorders like schizophrenia – which alone affect 25 million people worldwide– have
poor long-term outcomes, such as higher rates of unemployment, hospitalizations, and
suicide.6–8 There are also physiological outcomes associated with these disorders. For
example, schizophrenia is associated with increased cardiovascular disease11 and higher
rates of premature mortality.9 Similarly, the economic impact of psychotic disorders is
substantial and can be partially attributed to its emergence during adolescence and young
adulthood, as well as the fact that the mentioned symptoms and their corresponding
impact on health outcomes may persist throughout the lifespan.12 A 2016 systematic
review of studies examining the economic burden of schizophrenia determined that the
annual cost of this illness, in U.S dollars, ranged from $94 million to $102 billion (0.02%
to 5.46% of the gross domestic product).12 Lower estimates were partially explained by
some countries having tax-funded healthcare, but more general reasons for the wide
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range in costs included differences in: health care systems, resource use, types of costs
evaluated, and populations studied.12 In Canada, the financial burden of schizophrenia in
2004 was estimated to be approximately $6.85 billion, with nearly 70% of these costs
attributable to productivity losses – largely due to morbidity – whereas the remaining
30% was due to direct healthcare and non-healthcare costs.13 More locally, Ontario
estimates for 2012 direct health care costs of chronic psychotic disorders to the ministry
of health was about $10,398 per patient.14 Overall, psychotic disorders are associated
with negative long-term health outcomes, which contribute to large economic burdens on
a national and global level.
There is evidence to suggest that the longer one waits to diagnose and treat the first
episode of psychosis (FEP), the poorer the prognosis.15,16 Knowing that poorer outcomes
may further contribute to the health burden and subsequent economic costs associated
with psychotic disorders, early research in the field sought to examine the course of
illness and clinical stages in which intervention may be appropriate. Eventually,
researchers were able to observe a prodromal phase that often preceded the first psychotic
episode, characterized by increasing psychotic symptoms and a decline in functioning.6,17
This prodromal stage was often only identifiable retrospectively – once symptoms of
psychosis emerged – since prodromal features can be fairly non-specific.6 Nevertheless,
there are subthreshold symptoms and observable declines in functioning that can be
identified using systematic assessments prospectively.6,17 This clinical stage is known as
the ultra-high risk (UHR) state for psychosis, though other terms exist, such as the
clinical high risk state (CHR) or the at risk mental state (ARMS).6,18 These terms indicate
that though transition to psychosis is possible, it is not inevitable.6 Programs now exist to
treat those at UHR for psychosis,19 and trials have since been published to attest to their
clinical effectiveness.20 Unlike the clear clinical symptoms of the FEP diagnosis, the
UHR state is more challenging to identify due to the previously mentioned fact that only
some may go on to transition to psychosis.6,21 As a result, there are now assessment tools
in development – such as individualized risk calculators – which compute a probability
for the risk of transitioning to psychosis among people identified as UHR.22
Individualized risk scores may then allow future treatment plans to offer more
personalized and intensive intervention to those with higher transition probabilities. With
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limited funds available for mental health treatment, there is value in modeling assessment
tools that allow prioritized allocation of scarce resources in order to estimate their
potential cost-effectiveness in the context of UHR clinics.

1.1.1

Summary of Thesis Layout

The purpose of this thesis is to identify and address gaps in the literature regarding the
economic value of UHR programs. We aim to investigate the economic value of
allocating treatment for UHR patients based on an individualized risk calculator that
computes the probability of transitioning to psychosis – those with higher risk scores
would be enrolled in more vigorous case management strategies compared to those with
lower scores. We first systematically reviewed the literature on economic evaluations of
UHR programs. We then created an economic model examining the cost-effectiveness of
providing annual risk assessments to UHR patients at low risk of transitioning and UHR
treatment (active case management) to those at high risk, compared to treating all UHR
patients with UHR treatment irrespective of risk. This thesis follows an integrated format,
which includes published and unpublished manuscripts. Chapter 1 will provide
background information and will detail concepts pertinent to the UHR state, current
evidence regarding the effectiveness of early psychosis intervention programs, and
describe assessment tools available for the UHR state. Chapter 2 will present a published
systematic review manuscript of available health economic evaluations completed on the
UHR population, and identify the current gaps in the literature on this topic in order to
inform the analyses in later chapters. Chapter 3 will present the unpublished manuscript
of the economic evaluation, detailing the results of the base case analysis and sensitivity
analysis. Chapter 4 will contain an extended discussion of the results and integration of
findings across the two manuscripts, including future directions.

1.2

First Episode Psychosis Programs and Treatment

An episode of psychosis occurs when a person is unable to determine what is or is not
reality.2,3 In recent decades, there has been an emphasis on early intervention for the first
psychotic episode2,3 and for those identified as being at UHR of transitioning to
psychosis.17 The main goal of early psychosis intervention is to provide comprehensive
treatments to those experiencing symptoms indicative of psychosis (FEP stage) or
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impending psychosis (UHR stage),6 with the latter aimed at preventing transition to full
psychotic disorder. The types of treatments may vary depending on the stage, but are
ultimately aimed at preventing poor long-term outcomes, and potentially avoiding the
FEP stage completely if administered during the UHR stage.6

1.2.1
First Episode Psychosis and Duration of Untreated
Psychosis
Psychotic episodes are characterized by positive and negative symptoms.2,3 Positive
symptoms include delusions, hallucinations, and disorganized speech, thoughts or
behavior.2,3 Negative symptoms include alogia (restricted speech), avolition (reduced
motivation), and affective flattening (limited facial expression).2,3 In addition to the
distress and confusion one may feel from the onset of their first psychotic episode, there
may also be a delay in receiving prompt treatment. Although specific definitions vary, the
period between the onset of the first psychotic symptom and the commencement of
antipsychotic treatment is termed the duration of untreated psychosis (DUP).23 A long
DUP is associated with unfavorable clinical outcomes, some of which may include an
increase in the severity of positive and negative symptoms and a lower likelihood of
remission.24

1.2.2

First Episode Psychosis Programs

In an effort to reduce the DUP and improve outcomes, FEP programs have been
developed to provide intensive treatment during the early phases of psychosis. They use
personalized treatment plans involving both medication and therapy – which may include
family intervention and social skills training – overseen by a multidisciplinary team of
mental health professionals.5,8,25 FEP programs are usually provided in the first two years
after the onset of psychosis, though it has been suggested that an extension of the
program for up to five years may be needed to improve patient outcomes.26,27 Quality
treatment during this ‘critical period’ is essential in order to improve long-term outcomes,
especially given that patient disengagement from services may occur at this time.6
Worldwide, the effectiveness of FEP programs has been established.5 A 2018 systematic
review and meta-analysis by Correll et al5 showed that programs for early-phase
psychosis were more effective in treating FEP compared to standard care across all

5
outcome indicators examined – this includes all-cause treatment discontinuation and
psychiatric hospitalization. More locally, in a cohort of incident cases of nonaffective
psychosis in the London catchment area, all-cause mortality rates were four times lower
among people who used the FEP service, compared to non-users.16
Independent economic evaluations have also found FEP programs to be cost-effective in
a variety of settings.28–30 A 2019 systematic review found FEP programs to be potentially
cost-effective, though the heterogeneity in the methodology, health contexts, and
treatment plans between FEP programs – among other limitations – contribute to the
uncertainty in the conclusions.31

1.3

The Ultra-High Risk Concept

Due to the poor outcomes and increased costs associated with treatment delay following
the first psychotic episode, there has been an increased interest in examining an earlier
clinical stage – the UHR stage – to pre-emptively treat early symptoms of psychosis.17
Those in the UHR stage may experience changes in normal constitution, such as anxiety,
a reduced motivation to attend school or work, and the emergence of subthreshold
positive symptoms.2,17,32 Much like those who have transitioned to FEP, people identified
as UHR may also experience comorbid non-psychotic disorders, such as depression and
anxiety.33 Because some of these symptoms may be indicative of other mental illnesses,
people must meet at least one of the following criteria to be considered UHR: (i)
attenuated psychotic symptoms (APS); (ii) brief limited intermittent psychotic symptoms
(BLIPS); or (iii) genetic risk and deterioration (GRD).17,34 APS describes subthreshold or
mild symptoms experienced in the past year that do not meet the diagnostic criteria for a
psychotic disorder.17 BLIPS refers to short periods of frank psychotic symptoms that
disappear without treatment within a week.17 GRD may refer to either the presence of a
psychotic disorder within a first-degree family member or evidence of declining
functioning and a diagnosis of schizotypal personality disorder in the person being
examined.17 Usually, identification of the UHR state is restricted to adolescents and
young adults between the ages of 14 and 30.17 Different psychometric instruments may
be used to determine if someone is UHR, though some popular assessment tools include
the Comprehensive Assessment of At-Risk Mental States (CAARMS)35 interview and the
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Structured Interview of Prodromal Syndromes (SIPS).36 CAARMS and SIPS have
previously been shown to be acceptable assessment tools to identify the UHR state.37,38

1.3.1
The Risk for Transition from the Ultra-High Risk State to
First Episode Psychosis
An early proof of concept study by Yung et al39 in 2003 found that approximately 40% of
people at UHR for psychosis transitioned to psychosis within a year, though more recent
estimates from a 2015 meta-analysis have determined that this number may be as low as
about 10% at six months to 37% over four years.40 These transition probabilities are still
reasonable, given that other risk states exist with comparable values.18 The pre-diabetic
classification with a 5% to 10% chance of transitioning to diabetes,18,41 and the 12%
chance of conversion to dementia from mild cognitive impairment,42–44 are two examples.
Some theories exist as to why there have been recent declines in transitions to psychosis.
One theory suggests that transition rates may be declining because treatment is being
appropriately and swiftly provided to those early in the course of illness.45 Another
reason was provided by a meta-analysis of recruitment strategies to UHR clinics.46 This
study found that the declining transition risk may be explained by a high proportion of
self-referrals from the general public, rather than referrals from mental health care
providers.46 Specifically, it was argued that intensive outreach campaigns – especially
ones that capture a high number of self-referrals – may draw potential patients from a
population that may exhibit UHR symptoms that would be considered to be benign or not
clinically significant.42,46 Patients exhibiting these milder UHR symptoms may never
transition to psychosis, resulting in risk dilution.42,46 Another potential reason for the
recent declines in transitions was suggested by Simon et al,42 who stated that some nonpsychotic disorders may have psychotic-like symptoms, such as anxiety and depression.
People presenting to UHR programs with psychotic-like symptoms attributable to other
disorders may then meet the criteria for APS, but not actually transition.42 Finally, given
that most studies examine transitions to psychosis within two years, there is the
possibility that additional transitions that occur after this time may not be captured.42
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1.3.2

Ultra-High Risk Programs

Programs targeting people identified as being in an UHR state have been developed with
an aim of encouraging early engagement with essential treatments and services for
distressed youth, to potentially delay or prevent the transition to psychosis.47 In addition,
these programs may provide an opportunity to improve clinical outcomes by lowering the
chances of being admitted to the hospital during a crisis and by also reducing the
DUP.47,48 UHR programs tend to be a mixture of active case management,
pharmacological treatments, psychosocial therapies, and additional therapies.19 It is
important to note that Canadian guidelines – which are derived from the European
Psychiatric Association and National Institute for Health and Care Excellence guidelines
– recommend that antipsychotics should not be used in preventative treatments plans for
mild cases.49 Similar to FEP programs, UHR programs provide support to patients for a
duration of about two years, and may be extended depending on need.19,50
There are numerous UHR programs world-wide. For example, the Outreach and support
in South London (OASIS) program is one of the largest and most well-established UHR
programs in the UK.50–52 In Canada, the Montreal Clinic for Assessment of Youth at Risk
(CAYR) program has been active for over ten years,19 and more locally, the PROSPECT
(PROdromal Symptoms of Psychosis: Early Clinical identification and Treatment) clinic
has been operating since 2018.
Several prior systematic reviews and meta-analyses examining the clinical effectiveness
of UHR programs have yielded inconclusive findings.53 A review of seven meta-analyses
on interventions targeting people identified as UHR found that the results did not
adequately determine whether one intervention was favored over another or favored over
a control condition.53 Similarly, a 2019 Cochrane systematic review reported individual
studies that did not find evidence in favor of one intervention over the alternative.54 For
example, there was no significant difference in outcomes when comparing a cognitive
behavioral therapy (CBT) and risperidone combination treatment to CBT with a
placebo.54 It must be noted that the studies included in the review were of low quality and
affected the ability to draw firm conclusions on the effectiveness of any of the treatment
combinations over an alternative.54 It should also be noted that control groups are not
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completely untreated due to the ethical concerns in denying treatment to help-seeking and
distressed individuals.45 Therefore, when comparing interventions to these treated
controls, the lack of a significant difference in outcomes could suggest equal
effectiveness between groups instead of neither intervention being effective.45 Despite
these limitations, there are still studies supporting the clinical effectiveness of UHR
programs. For example, in the same 2019 Cochrane review, researchers found that a
combination of supportive therapy and CBT yielded fewer transitions to psychosis (8% in
the intervention group), with twice as many transitions in the control group who were
engaged in supportive therapy alone.54 Similarly, omega-3 fatty acids have also shown
some promising results.54 As UHR programs continue to operate and expand world-wide,
so too must efforts increase in establishing the true clinical effectiveness of UHR
interventions and the corresponding economic impacts of these treatment strategies.

1.3.3

Limitations to the Ultra-High Risk Concept

The UHR concept itself is not without limitations. Firstly, prior research suggests that
there is stigma associated with the UHR state,7,17,55 which may contribute to reduced
well-being.55 However, when one study examined how stigma was perceived by UHR
patients, compared to health professionals, the patients thought that the ‘UHR’ and ‘APS’
labels were both less stigmatizing and less likely to be a cause of fear or shame,
compared to the opinions of mental health professionals.56 In fact, UHR patients have
previously expressed that the symptoms are more stigmatizing than the label itself.57
Rather, it is the patients who had transitioned to FEP or had family members with
psychosis who were more likely to find the term ‘UHR’ stigmatizing.56 Interviews with
UHR patients following treatment have shown that they find value in the care given by
staff.58
Another limitation of the UHR concept is that high-quality studies on the effectiveness of
UHR programs are still lacking.54 As mentioned previously, it is challenging to examine
the true clinical effectiveness of intervention on UHR populations when control groups
cannot be completely untreated due to ethical concerns associated with denying treatment
to help-seeking and distressed individuals.45 Regardless, there is some promise in
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improving outcomes among those at UHR for psychosis with certain interventions, such
as omega-3 fatty acids and CBT with supportive therapy.54
A final limitation of the UHR concept is that there has been a global decline in the risk of
conversion to FEP over time,46 which may lead to concerns regarding whether treatment
from UHR programs is necessary or being appropriately provided to patients. As
mentioned previously, transition risks may be lower because of effective early
treatment.45 In addition, the ability of the UHR concept to predict transition to FEP is still
reasonable given that other prodromal states – such as the 12% chance of transitioning to
dementia from mild cognitive impairment – have comparable values.42–44 The decline in
transitions to FEP helped influence novel research concerning the creation of assessment
tools that can better predict transitions and provide more personalized transition risk
scores to better inform treatment plans for UHR symptoms that differ in severity.

1.4

Assessment Tools for the UHR State

Treating schizophrenia is costly to the health system, with productivity losses amounting
to about $4.83 billion in 2004 in Canada alone.13 UHR programs are beneficial in that
they aim to treat patients exhibiting symptoms that precede a psychotic episode to
potentially avoid the costs associated with the long-term course of psychotic illness and
future negative outcomes. Of equal importance are the assessment tools used to
determine who meets the UHR criteria and who will then have access to the scarce
resources for treatment provided by the UHR programs.
UHR clinics may use a myriad of assessment tools to determine whether an individual
meets the UHR criteria. Unfortunately, one of the limitations of the UHR concept is the
low risk of transitioning to psychosis, which may impart additional costs from treating
those who are unlikely to transition, despite being identified as UHR by these assessment
tools.42,46 Research in the field has sought to address this concern through the use of
individualized risk calculators that distinguish between those among the UHR population
who are more likely to transition to psychosis compared to less severe UHR cases.22
Individualized risk calculators for psychosis provide a score that estimates the likelihood
for a person to transition to psychosis based on several risk factors, which are usually
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incorporated into a multivariable model.59 Established UHR clinics could benefit from
using risk scores to help inform the best way to allocate resources to maximize treatment
effectiveness. Current practice in UHR clinics usually involves an initial assessment of
help-seeking individuals using well-established instruments to identify the UHR state,
such as CAARMS and SIPS, before a treatment plan is determined based on presumed
need.

1.4.1

Current Assessment Tools to Identify the UHR State

Typically, in order to receive treatment at an UHR clinic, a help-seeking individual needs
to meets the criteria for the UHR state. In North America, CAARMS and SIPS are
commonly used in UHR clinics to determine whether a person meets said criteria.17,49 In
Montreal, the CAYR clinic uses CAARMS,19 whereas the more local London
PROSPECT clinic uses SIPS. A meta-analysis of the prognostic accuracy of these tools
to predict transition to psychosis found the sensitivity of these prognostic tools –
specifically, the proportion of people who transition to psychosis and test positive on the
tool – to be very high [SIPS: 0.96 (95%CI = 0.88, 0.99) and CAARMS: 0.96 (95%CI =
0.82, 0.99)].60 Unfortunately, the specificity – specifically, the proportion of people who
do not transition to psychosis and test negative – was low for both tools [SIPS: 0.39
(95%CI = 0.32, 0.46) and CAARMS: 0.56 (95%CI = 0.38, 0.73)].60 Although an ideal
test would have both high sensitivity and specificity, these tools are considered to have
excellent prognostic accuracy for conversion to psychosis if they are used by
appropriately trained staff on a help-seeking population.60

1.4.2
The North American Prodrome Longitudinal Study
(NAPLS) Individualized Risk Calculator
Though CAARMS and SIPS are highly sensitive tests, their low specificity could result
in a high false positive rate, which means that there could be unnecessary treatment given
to individuals who may not actually transition to psychosis. As a result, current research
in early psychosis seeks to identify potential variables that may improve the prediction
accuracy of transitioning to psychosis among people identified as UHR. Variables may
include: index diagnosis, age, sex, and ethnicity.51,61 Unfortunately, a previous systematic
review examining risk prediction tools for transition to FEP found that many depended
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on small sample sizes for model development and lacked external validation.59 Yet, there
are some risk prediction tools that show promise.
One risk prediction tool of interest is the North American Prodrome Longitudinal Study
(NAPLS) individualized risk calculator, which is a tool that offers an individualized score
between zero and one that corresponds with the probability of transitioning to
psychosis.22 This calculator is one of several research products derived from the NAPLS
research study, which involves a cohort of 764 UHR participants and 280 healthy
controls located in eight sites in North America – University of California Los Angeles
(UCLA), Emory, Beth Israel Deaconess Medical Center, Zucker Hillside Hospital,
University of North Carolina (UNC), University of California San Diego (UCSD),
Calgary, and Yale.22,62 This study follows the largest cohort of UHR participants to
date.62
The risk predictions from the individualized calculator are modelled from a sample of the
NAPLS cohort, consisting of 596 UHR patients followed over two years.22 Participants
were recruited between 2008 and 2013 and were followed up until they transitioned to
psychosis or up to two years.22 The NAPLS risk calculator is based on a cox proportional
hazards regression model22 and has since been externally validated in different
populations.63–65 In order to use the risk calculator, participants need to be identified as
UHR by SIPS.22 The NAPLS calculator determines transition risk based on the following
eight variables that describe demographic, cognitive, and clinical characteristics: age,
unusual thought content and suspiciousness, processing speed, verbal learning and
memory functioning, social functioning, stressful life events, childhood traumas, and
family history of psychotic disorder.22
The NAPLS risk calculator is currently being used for research purposes and shows
excellent predictive capability.22 Specifically, the Harrell C index score was used to
determine how well each variable could distinguish between converters to psychosis and
non-converters.22 The index score ranges between 0.5 to 1, with higher values indicating
better discrimination between converters and non-converters.22 The NAPLS risk
calculator (cox model) achieved an acceptable score of 0.714.22 Similar to the results of
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the internal performance assessment, external validation in an independent sample from
the United States (U.S) found that this risk calculator continued to display acceptable
predictive capability (Harrell C index score = .790).64 Additional external validation in
another U.S sample, published by Osborne et al,63 determined that the calculator showed
moderate discrimination ability based on the Area Under the Curve (AUC) score, which
provides the same information as Harrell C (AUC = 0.71). One assumption that must be
made when administering the NAPLS risk scores is that the sample must be inherently
similar to the NAPLS (North American) cohort in which the original cox model was
developed from.22 Yet, even when used on a Chinese (Shanghai) population, the AUC
score of the risk calculator was still fair (AUC = 0.631).65 Overall, the individualized risk
calculator shows potential to be used worldwide as long as future external validation
studies both inside and outside of North America continue to show favorable results.
In the NAPLS cohort, more non-converters to psychosis were observed compared to
converters among those with a risk score below 0.20.22 In contrast, at a risk level of 0.20
or higher, there were more converters relative to non-converters in their respective risk
categories.22 These findings suggest that we could consider providing more intensive
treatment plans to those in the higher risk categories (≥0.20 or ≥20% risk to transition), as
they have more people transitioning to psychosis compared to lower risk categories
(<0.20 or <20% risk to transition). Overall, there is potential to make future decisions on
treatment allocation in UHR clinics based on the level of risk determined by the NAPLS
calculator.22 In fact, the NAPLS tool has been used in local settings at the London
PROSPECT clinic to record NAPLS risk scores at baseline, but has not yet been used to
guide clinical decision-making.

1.5

Thesis Rationale and Objectives

A recent 2019 review by Yung et al18 suggested that there is value in UHR programs
because they provide a service for people who are distressed and will likely develop
negative outcomes during the course of the illness. With the appearance of UHR
programs worldwide, and with limited budgets allocated to mental health research, it is of
great importance to identify and address gaps in the literature regarding the economic
value of these programs. Though literature is available examining the cost66 and cost-
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effectiveness31 of early psychosis intervention programs (both FEP programs and UHR
programs together), these are predominantly focused on FEP rather than UHR.31 At this
time, there is no recent systematic review examining UHR programs exclusively.
Therefore, a comprehensive review of all current economic evaluations of UHR programs
is required. Understanding the state of the literature on the economic value of UHR
programs will inform future economic evaluations.
A further exploration of available tools to allocate care to those in need and minimize
costs in UHR programs may benefit already established Canadian clinics, such as the
Montreal CAYR clinic and the more local London PROSPECT clinic. Previous work by
Cannon et al22 has shown that those who score <0.20 on the NAPLS risk calculator (in
the risk classes: 0.01-0.04, 0.05-0.09, 0.10-0.14, and 0.15-0.19) had more non-converters
to psychosis compared to converters in their respective risk classes, while those who
score values that are ≥0.20 (from risk classes: 0.20-0.24 to 0.60-0.64) show the opposite
trend. Therefore, severe UHR cases may be categorized by scores that are ≥0.20 and less
severe cases may be seen as scores that are <0.20. The NAPLS calculator may help
maximize efficiency by allocating already scarce resources to severe cases at risk for
transitioning to psychosis, while providing less severe cases with yearly risk assessments
to monitor risk levels. The London PROSPECT clinic already uses the NAPLS calculator
for research purposes, so understanding the cost-effectiveness of priority-based treatment
based on NAPLS scores in a Canadian context may help inform the potential utility of
these scores in a clinical setting.

1.5.1

Thesis Objectives

This thesis uses an integrated style format and is divided into two manuscripts, which are
aligned with the thesis objectives:
1. The first objective was to conduct a systematic review of prior literature on
economic evaluations of the UHR population.
2. The second objective was to create an economic model examining two different
strategies to intervene on those at UHR for psychosis. We determine whether
cost-effectiveness is impacted by either the use of a risk stratification strategy or a
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‘treat all’ treatment strategy in the context of a UHR clinic. Specifically, the risk
stratification treatment strategy will provide UHR treatment (active case
management) to those who receive high risk scores through the NAPLS calculator
(predicted risk to transition ≥20%), while less severe cases (predicted risk to
transition <20%) are provided an annual risk assessment using the NAPLS
calculator to monitor risk levels. The alternative treatment strategy provides UHR
treatment to all patients, regardless of their risk level.
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Chapter 2
2

Interventions for People at Ultra-High Risk for

Psychosis: A Systematic Review of Economic Evaluations
This is the peer reviewed version of the following article: [Ologundudu OM, Lau T,
Palaniyappan L, Ali S, Anderson KK. Interventions for people at ultra-high risk for
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doi:10.1111/eip.13061], which has been published in final form at
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non-commercial purposes in accordance with Wiley Terms and Conditions for Use of
Self-Archived Versions [https://authorservices.wiley.com/author-resources/JournalAuthors/licensing/self-archiving.html]. See Appendix D for further licensing details
regarding use of this peer reviewed version of the manuscript in this thesis/dissertation.
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2.1

Abstract

Aim: Psychotic disorders have long-term negative consequences for functioning and
quality of life. Ultra-high risk (UHR) programs aim to identify and treat people during
the prodromal period before their first psychotic episode. Though studies on the clinical
effectiveness of treating prodromal symptoms in people at UHR for psychosis exist, no
review has exclusively and comprehensively evaluated the economic impact of UHR
programs. Our objective was to systematically review the literature on economic
evaluations of UHR programs. Methods: We searched the Cochrane, EMBASE,
MEDLINE, and PsycInfo electronic databases, in addition to grey literature, from
inception to March 2020 to identify economic evaluations of UHR programs. We
included all cost and cost-effectiveness studies of interventions for people at UHR. The
data were synthesized qualitatively, and a risk of bias assessment was performed.
Results: Of the 1,916 articles retrieved, six studies met our inclusion criteria. These
included three cost analysis studies and three cost-effectiveness studies. Five studies were
conducted from the health system perspective and the time horizon varied between six
months and ten years. Only two reported quality-adjusted life-years (QALYs) as their
outcome. Overall, all cost-effectiveness studies and one cost analysis suggested that UHR
programs were cost-effective and cost saving, respectively. The risk of bias assessment
suggested moderate levels of bias across all studies. Conclusion: Economic evaluations
of UHR programs varied in terms of outcomes and length of follow-up; however, most
studies found them to be cost-effective. Future studies would benefit from long-term
evaluations of UHR programs and consistent valuation of outcomes.
Keywords
Cost-Benefit Analysis, Costs and Cost Analysis, Prodromal Symptoms, Psychotic
Disorders, Schizophrenia
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2.2

Introduction

Psychotic disorders are debilitating mental illnesses that are associated with negative
effects on quality of life and functioning, especially when the course of illness is
characterized by cycles of relapse and remission.17,67 The pooled worldwide incidence of
psychotic disorders is estimated to be about 26.6 cases per 100,000 person-years (95% CI
22.0–31.7).10 Psychosis, a symptom of psychotic disorder, is often associated with
comorbid disorders that further contribute to future negative health outcomes.6,33
Examples of comorbid disorders include: substance use disorders, depression, and
anxiety.33 Given the fact that episodes of psychosis can have negative consequences not
only for the affected person, but also for their family and society, treatment strategies
have been devised to intervene early in the course of illness. These early psychosis
intervention programs have been shown to be effective in treating people experiencing
their first episode of psychosis in a variety of settings.5,16,68 One systematic review
concluded that early psychosis intervention programs are superior to treatment as usual
for improving global functioning, symptom severity, and quality of life, while also
lowering rates of relapse and all-cause treatment discontinuation.5
Given the effectiveness of early psychosis intervention programs, there has been
increasing interest in intervening at an earlier stage, with an aim of preventing the first
episode of psychosis, known as the ultra-high risk (UHR) paradigm. Those at UHR for
psychosis have not yet experienced a first episode of psychosis, but are at an increased
risk to do so based on genetic and psychometric evaluations69 – these include the
Comprehensive Assessment of At-Risk Mental States35 and the Structured Interview of
Prodromal Syndromes.36 People at UHR for psychosis may experience depression and
anxiety33 and have substantial functional impairments.69 As well, the young age at
presentation – between 14 and 30 years – means there could be significant implications
for social, educational, and professional development.17 A systematic review on UHR
programs suggests that treatment during this phase of illness may delay or prevent
transition to first-episode psychosis, but limitations, such as the high attrition in this
population, affect the strength of this effect.7 Although there is evidence that UHR
programs may be effective in reducing transition rates to psychosis, long-term
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effectiveness may diminish once the program ends.70 Furthermore, intervention among
people at UHR for psychosis is especially challenging, given that only a small percentage
will ultimately transition to a first episode of psychosis.17,22 For instance, an estimated
10% and 37% of people identified as UHR will go on to transition to psychosis within six
months and four years, respectively, though this number may vary depending on the
study population and other methodological considerations.40
Despite these challenges, interventions for people identified as UHR for psychosis have
been incorporated into clinical practice guidelines. For example, the European Psychiatric
Association compared seven randomized controlled trials (RCT) examining UHR
programs and found that the risk of conversion to psychosis was reduced by 56% at 12
months – these results have contributed to the recommendations for care in the UK and
countries like Canada.49,71 There has been a growing number of UHR programs
worldwide, and with this proliferation comes debate regarding the cost-effectiveness of
this prevention strategy. A systematic review from 2012 was inconclusive regarding
whether UHR programs are cost-saving in different health care settings, and this review
included both recent-onset psychosis and UHR populations.66 A 2019 systematic review
on early intervention for psychosis – also including both UHR and first-episode psychosis
populations – found that these programs may be cost-effective during the program’s
duration. However, this review only included cost-effectiveness analyses, and did not
focus exclusively on the UHR population.31 An update to this evidence base that focuses
exclusively on UHR populations and includes both partial and full economic evaluations
is warranted in order to provide a comprehensive assessment of the potential economic
impact of UHR programs.
The objective of this study was to conduct a systematic review of economic evaluation
studies examining the cost and cost-effectiveness of interventions for people identified as
UHR for psychosis.
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2.3

Methods

We used the Preferred Reporting Items for Systematic reviews and Meta-Analyses
(PRISMA) guidelines for this review, and the completed checklist can be found in the
Supporting Information document (Appendix A).72

2.3.1

Information Sources and Search Strategy

We searched the Cochrane, EMBASE, MEDLINE, and PsycInfo databases from
inception to September 2019 for economic evaluations of interventions targeted to the
UHR population, and updated the search in March 2020. The types of studies examined
included partial (cost analyses) and full (cost-effectiveness, cost-utility, and cost-benefit)
economic evaluations.73 We used a combination of keywords and controlled vocabulary
adapted to each database using their unique syntax. These keywords included: (at risk
mental state* OR ARMS* OR psychosis risk* OR psychosis prediction* OR psychosis
onset* OR prodrom* OR prodromal psychosis* OR high risk* OR ultra-high risk* OR
ultra high risk* OR UHR OR CHR OR clinical high risk* OR clinical-high risk* OR
high clinical risk* OR referr* OR help seeking* OR progression to first-episode
psychosis*) AND (economic evaluation* OR health economic* OR cost-effectiveness*
OR cost-benefit* OR cost analysis) AND (Psychosis OR psychotic OR schizophreni* OR
sever* mental ill* OR sever* mental disorder* OR psychiatric crisis* OR crises*). We
also searched the grey literature, including the ProQuest database for dissertations and
theses and the Scopus database. Forward and backward citation tracing of included
studies was used to identify any articles missed by our electronic search strategy.
Complete details on the keywords and controlled vocabulary used for all databases and
grey literature sources can be found in Online Supplement 2 (Appendix B).

2.3.2

Eligibility Criteria and Study Screening

To be included in our systematic review, studies had to meet the following inclusion
criteria: 1) The sample included people identified as “ultra-high risk (UHR)”, “clinical
high risk (CHR)”, or “at risk mental state (ARMS)” for psychosis, with no restrictions on
age, country of origin, or comorbidities at baseline; 2) The study conducted an economic
evaluation relating to intervention in the UHR group using randomized trials,
observational studies, simulated data, or a model; and 3) The study used an outcome
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examining cost, quality-adjusted life years (QALY), incremental cost-effectiveness ratio
(ICER), or a cost/effectiveness measure. There were no limits on follow-up time, but we
restricted studies to the English language.
We excluded studies where the main focus of the economic evaluation was not on
intervention in an UHR sample, studies that only briefly mentioned economic costs or
outcomes, studies examining only clinical effectiveness, as well as reviews, abstracts, and
other non-peer reviewed publications.
Level one screening (title and abstract) was conducted by one reviewer (O.M.O), and
level two screening (full text) was conducted independently by two reviewers (O.M.O &
T.L). Any disagreements concerning the inclusion of studies in the systematic review
were resolved by discussion with a third reviewer (K.K.A).

2.3.3

Data Extraction and Risk of Bias Assessment

A standardized form was created and pilot tested to extract information from included
articles. We extracted information on key variables, including: authors, year, country,
type of economic evaluation, intervention and comparator details, sample size, cost
measure, effectiveness measure, major model assumptions, time horizon, perspective,
transition probabilities, results, and noteworthy limitations. Where data were missing,
previous publications from the same study were accessed to fill in missing information.
We used two risk of bias tools recommended by the Cochrane Collaboration: the
Consensus on Health Economic Criteria (CHEC) checklist,74 and the International
Society of Pharmacoeconomics and Outcomes Research (ISPOR) checklist, with the
latter used specifically for the model-based evaluations, given that it provides additional
criteria relevant to this type of study.75 Risk of bias assessments were based only on the
included article and supplementary documents, and did not incorporate information
available from other referenced articles or protocols. For the CHEC checklist, studies
were given numerical scores out of 19 (cost-effectiveness studies) or 15 (cost analyses).
Model-based evaluations were similarly scored on the ISPOR checklist (out of 15).
Assessments of the risk of bias were based on CHEC scores for trial-based evaluations,
and both CHEC and ISPOR scores for model-based evaluations.
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The data were extracted by one reviewer (O.M.O.) and verified by a second reviewer
(T.L.). Two reviewers (O.M.O. & T.L.) completed the risk of bias assessments
independently. Discrepancies in either the data extraction form or the risk of bias
assessments were resolved between the reviewers, with a third reviewer (K.K.A.)
involved where a consensus could not be reached.

2.3.4

Synthesis of Results

We synthesized the findings qualitatively. We were unable to conduct a meta-analysis
due to heterogeneity in the context or setting of the economic evaluations, such as
currency used and mental health care structure in the country, as well as inconsistent
outcome measures across the studies.

2.4

Results

2.4.1

Study Selection

Our search strategy retrieved 1,438 articles from the electronic databases and 378 articles
from grey literature. A total of 1,316 articles remained after the removal of duplicates.
From this initial search, 20 articles were eligible for full-text screening. An updated
search from September 2019 to March 2020 returned an additional 100 articles, one of
which was also eligible for full-text screening. Of the 21 articles screened, 14 articles
were excluded for the following reasons: duplicate populations (n=5); not UHR sample
(n=3); review article (n=2); abstract only (n=2); only examines comorbidity (n=1); and
inappropriate outcome (n=1). In total, six studies met our inclusion criteria for qualitative
synthesis, with one unique study published across two reports.20,76–81 Figure 2.1 provides
a flowchart that outlines the selection process.

Identification

22

Records identified through
database searching
(n = 1538)

Additional records identified
through other sources
(n = 378)

Included

Eligibility

Screening

Records after duplicates removed
(n = 1416)

Records screened
(n = 1416)

Full-text articles assessed for
eligibility
(n = 21)

Studies included in
qualitative synthesis
(n = 7 reports from 6 studies)

Records excluded
(n = 1395)

Full-text articles
excluded, with reasons
(n = 14)
•
•
•
•
•
•

Duplicate
populations
(n = 5)
Not UHR (n = 3)
Review (n = 2)
Abstract (n = 2)
Examines
comorbidity
(n = 1)
Inappropriate
outcome (n = 1)

Figure 2. 1 Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flowchart of included and excluded studies in the selection process

Figure 2.1 Preferred Reporting Items for Systematic reviews and Meta-Analyses
(PRISMA) flowchart of included and excluded studies in the selection process72
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2.4.2

Characteristics of the Studies and UHR Programs

The characteristics of included studies are summarized in Table 2.1. Four of the included
studies were model-based economic evaluations, and the remainder were trial-based
(n=2). Five studies compared UHR programs to routine care. The one exception
examined whether a high- or low-intensity liaison between general practitioners and
mental health services could improve referrals of people at UHR for psychosis to mental
health services, relative to standard practice.80
The UHR programs were similar in that they often consisted of a combination of
pharmacological, psychosocial, and other therapies. Cognitive behavioral therapy (CBT)
was the most frequently used psychosocial intervention and was part of the UHR
program in three of the included studies.20,77,79,81 Cognitively oriented psychotherapy76 –
which was part of a specific preventive intervention program – and an unspecified
psychosocial intervention78 were also mentioned. Often, the UHR program would be
comprised of routine care supplemented with CBT20,79,81 or a specific preventive
intervention program.76 If pharmacological treatment plans were included in the UHR
program, they typically involved a low-dose antipsychotic or an antidepressant.77 Specific
drugs mentioned included: risperidone (mean dose range: 0.5–2 mg)76,78 or quetiapine
(25–75 mg).78 Additional supplementary therapies included supportive counselling and
regular case management.76 Routine care involved typical treatment plans common for
non-psychotic Axis 1 or Axis 2 disorders,20,79,81 no treatment specific to the UHR state,77
needs-based treatment (supportive counselling, regular case management, and occasional
medication),76 or unspecified care at a Child and Adolescent Mental Health Service.78

2.4.3

Types of Economic Evaluations

Of the trial-based studies (n=2), one was a cost analysis and one conducted both a costeffectiveness analysis and a cost-utility analysis. Of the model-based studies (n=4), two
were cost analyses and two were cost-effectiveness analyses. Different cost perspectives
were used, including a health system perspective (n=4), a societal perspective (n=1), and
both a health system and societal perspective (n=1). The time horizon ranged from six
months to ten years. Two of the studies were based on participants from the Dutch Early
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Detection and Intervention Evaluation Trial in the Netherlands (EDIE-NL), and the
remaining studies originated in either Australia (n=1) or the UK (n=3).

2.4.4

Cost and Effectiveness Measures

Cost measures varied between the studies. Costs examined from a health system
perspective included: outpatient costs, inpatient costs, and medication costs.76–78 The
study by Perez et al80 included liaison service costs, diagnostic costs, and costs for the
referrals. The two studies that examined costs from a societal perspective included lost
productivity costs in addition to the associated health system costs.20,77 The authors of
included studies used various strategies to deal with cost uncertainty, such as using a
gamma distribution for cost values,80,81 considering a societal perspective in addition to
the health system perspective,20 varying the cost values,77,79,80 or using a bootstrap
method to estimate a 95% confidence interval of the mean cost difference between the
services.76 In one case, no explicit strategy for dealing with cost uncertainty was
described.78
Effectiveness measures varied greatly across the studies, with only two using QALYs
(EQ-5D three-level version). However, it is important to note that these two studies were
based on the same Dutch population – one unique study published across two reports
compared short and long-term outcomes,20,79 and the other modelled the population using
a Markov model.81 In instances where QALYs were not used, the number of true-positive
cases identified80 or averted transitions to psychosis20,79 were the alternative effectiveness
measures used.
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Table 2.1 Summary of study characteristics
Table 2. 1 Summary of study characteristics

Intervention
SPI

Control
NBI

Perspective
Health system

City/Country
Melbourne,
Australia

Valmaggia et al,77 2009

South London,
UK

Cost
analysis

Model

N/A

OASIS

CAU

N/A

Societal†

1&2

McCrone et al,78 2013

Teesside,
England

Cost
analysis

Model

N/A

EI

CAMHS

N/A

Health system

0.5

Ising et al,20,79 (2015,
2017)

Netherlands

CEA &
CUA

Trial

RCT

EDIE-NL

RC

95, 101

Health system‡

1.5

Netherlands

CEA &
CUA

Trial

RCT

EDIE-NL

RC

56, 57

Health system
& societal

4

Cambridgeshire
&
Peterborough,
UK
Netherlands

CEA

Model

N/A

LEGs (highand lowintensity)

PAU

N/A

Health system§

2

CEA

Model

N/A

CBT

CAU

N/A

Health system

10

Wijnen et al,81 2019

Trial
Design
RCT

Time
Horizon
(Years)
0.5, 1, & 3

Author, Year
Phillips et al,76 2009

Perez et al,80 2015

Study
Design
Trial

Sample Size
(Int., Ctrl)
31, 28

Analysis
Type
Cost
analysis

Abbreviations: CAMHS, Child and Adolescent Mental Health Services; CAU, Care as Usual; CBT, Cognitive Behavioral Therapy; CEA, Cost-effectiveness analysis; CUA, Cost utility analysis; EDIENL, Dutch Early Detection and Intervention Evaluation; EI, Early Intervention; LEGs, Liaison and Education in General Practice; NBI, Needs-Based Intervention; N/A, Not Applicable; OASIS,
Outreach and Support in South London; PAU, Practice as Usual; RC, Routine Care; RCT, Randomized controlled trial; SPI, Specific Preventive Intervention.
†Analysis includes costs with and without lost production, but did not include social care costs, criminal justice costs, or unpaid care and time off work associated with families and friends.
‡

Analysis included costs with and without productivity losses, but the authors explicitly stated that the perspective was a healthcare perspective.

§The perspective was not explicitly stated, but the health system perspective was assumed because productivity losses and criminal activity were not included.
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2.4.5

Findings of Economic Evaluations of UHR Programs

A summary of the results of the economic evaluations are provided in Table 2.2. Three of
the studies conducted cost analyses.76–78 The UHR programs were not found to be cost
saving in the studies by Phillips et al76 and Valmaggia et al77 over six and 12 months,
respectively. However, Phillips et al76 found the outpatient costs of the UHR program to
be cost saving between 12 and 36 months, with a mean cost of AU$4,101.60 (SD:
8,334.00) compared to AU$10,423.10 (SD: 25,277.30) in a needs-based intervention.
Despite this, the UHR program was not significantly different from a needs-based
intervention in terms of inpatient, outpatient, or total costs over the entire study period
(zero to 36 months). In contrast to these findings, McCrone et al78 found the UHR
programs to be associated with a cost savings of £4,814 per patient at six months, and
Valmaggia et al77 found a cost savings of £961 per patient at 24 months, compared to the
comparison intervention. Overall, cost results were heterogeneous across the three
studies.
Two of the included cost studies had a corresponding sensitivity analysis, which were
generally robust to changes in parameter inputs. Valmaggia et al77 conducted a one-way
sensitivity analysis and determined that the cost savings of UHR programs over routine
care were robust, but would revert if there was a large increase in the cost of care for the
UHR program or a reduction in costs to treat those who had experienced a long duration
of untreated psychosis. McCrone et al78 conducted a sensitivity analysis by changing
parameter values in their model by 50% in both directions and found that the preference
for UHR programs would remain unless there were substantial changes in the number of
admissions, length of stay, or cases of psychosis.
Three studies conducted cost-effectiveness analyses;20,79–81 however, one study did not
compare a UHR program to routine care.80 Ising et al20,79 conducted a cost-utility analysis
using QALYs, whereas Wijnen et al81 constructed a Markov model using the same UHR
program and population used by Ising et al.20,79 In terms of incremental costs, Ising et
al20,79 found that the UHR program was cost saving compared to routine care by about
US$844 and US$5,777 over 18 months and four years, respectively. Wijnen et al81 found
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that the cost of the UHR program at a projected ten-year follow-up still resulted in
savings of about €654 per patient. The QALYS were consistently larger in the UHR
program compared to the alternative at 18 months, four years, and ten years. Finally, the
bootstrap analyses of 2500 simulated ICERs found that CBT had a 26.2% probability of
being more cost-effective than routine care at 18 months at a willingness to pay (WTP) of
US$20,000, and a 92% probability at four years (WTP=US$24,560). One costeffectiveness study did not examine a UHR program, but was included in the qualitative
synthesis because it examined health care costs in the UHR population. Perez et al80
found that within two years, a high-intensity liaison service between general practitioners
and mental health services was more cost-effective compared to routine care – more true
positive cases were referred, resulting in greater cost savings.
All cost-effectiveness studies conducted a sensitivity analysis. Ising et al20,79 used last
observation carried forward imputation, Perez et al80 used a one-way sensitivity analysis,
and Wijnen et al81 used probabilistic sensitivity analysis. In all the analyses, the
conclusions in the main analyses were found to be robust to changes in the parameters.
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Table 2.2 Summary of study findings
Table 2. 2 Summary of study findings

Author, Year

Cost
(currency)

Outcome
(value)

Main Results

Sensitivity Analysis

Phillips et al,76 2009

1997
Australian
dollar

N/A

N/A†

Valmaggia et al,77 2009

UK pound

N/A

The SPI group had higher mean outpatient costs
compared to NBI during the 6 months of treatment
[AU$2,584.8 (SD: 2,522.4) vs AU$1,084.0 (SD:
940.0)]. Over the second follow-up from 12-36
months, SPI had lower mean outpatient costs
[AU$4,101.6 (SD: 8,334.0) vs AU$10,423.1 (SD:
25,277.3)]. Over 6 months and the 12-36 month
follow-up, there were no differences in inpatient,
pharmacological, and total costs.
Over 12 months, the OASIS intervention was £1,872
more expensive than CAU in terms of expected costs
(£2,596 vs £724). When comparing total costs at 24
months, OASIS was cost saving by £961 (£4,396 for
OASIS vs £5,357 for CAU).

McCrone et al,78 2013

UK pound

N/A

Over 6 months, EI had cost savings of £4,814 per
patient compared to generic CAMHS
(£13,186 for EI vs £18,000 for SC).

Ising et al,20,79 (2015,
2017)

2009 Euro,
converted to
US dollars

Averted
transitions
to
psychosis
& QALY

CEA: The incremental costs was US$844 in savings
and the incremental effect (risk difference) was 0.13
over 18 months. With bootstrap analysis (2500
simulated ICERs), CBT had a 63.7% chance of being
the dominant strategy compared to RC (i.e. less costly

One-way sensitivity analysis: The
model loses favor of OASIS over
CAU if there is a large change in
costs of DUP (if below £3841) or if
12-month care costs rises in OASIS
(above £3439).
Changing parameter values by 50%
in both directions: The model is
robust, unless there are changes in
admission (changing EI from 0.58 to
0.86 or SC from 0.58 to between 0.29
and 0.4 would make EI more
expensive), length of stay (changing
EI from 66% to excess of 97% to that
of SC makes EI more expensive), or
percentage of psychosis cases (over
67% for EI and less than 36% for SC
makes EI more expensive).
Sensitivity analysis using Last
Observation Carried Forward
imputation: Both CEA and CUA
sensitivity analyses were robust to
the previous conclusions.
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2014 Euro,
converted to
US dollars

Averted
transitions
to
psychosis
& QALY

Perez et al,80 2015

UK pound

Truepositive
cases
identified

Wijnen et al,81 2019

2018 Euro

QALY

and more effective). About 9.3% of simulated ICERs
fell below a WTP of US$20,000. CUA: Incremental
costs were unchanged (US$844 in savings). The
incremental QALY was 0.03. Bootstrap analysis
showed that CBT had a 52.3% chance of being the
dominant strategy compared to RC. About 26.2% of
simulated ICERs fell below a WTP of US$20,000.
CEA: The incremental costs were US$5,777 in savings
per participant. In the 4-year follow-up, the incremental
effect (risk difference) was 0.122 in favor of CBT.
With bootstrap analysis (2500 simulated ICERs), they
found an 82.9% probability that CBT is dominant due
to more averted transitions for less costs. The
intervention had a 92% probability of being costeffective at a WTP of US$20,000. CUA: More QALY
gains occurred in CBT, though this is not significant
(QALY difference = 0.164, P = 0.28). With bootstrap
analysis, they found a 74.8% probability of CBT being
dominant due to more QALY gains at a lower cost. The
intervention had a 92% probability of being costeffective at a WTP of US$24,560.
The high-intensity intervention was more costeffective. This practice referred the greatest number of
true positives, where the mean number of true-positive
cases identified per practice (SD) was 2.2 [1.7],
followed by low-intensity at 1.1 [1.7], then PAU at 0.6
[0.85]. The total 2-year cost per practice found highintensity practice to be the least costly (£26,785),
followed by the more expensive low-intensity practice
(£27,840), then PAU (£30,007).
CBT is dominant over CAU with a per-patient increase
of 0.06 QALYs and cost reduction of €654 per patient
over 10 years.

Sensitivity analysis using Last
Observation Carried Forward
imputation: Both the CEA and CUA
sensitivity analyses were robust to
the previous conclusions.

One-way sensitivity analyses: The
model was robust and rankings
remained unchanged (high-intensity
was dominant). Probabilistic
sensitivity analysis: This analysis had
similar results.

Probabilistic sensitivity analysis:
CBT is dominant.

Abbreviations: CAMHS, Child and Adolescent Mental Health Services; CAU, Care as Usual; CBT, Cognitive Behavioral Therapy; CEA, Cost-effectiveness analysis; CUA, Cost utility analysis; DUP,
Duration of Untreated Psychosis; EI, Early Intervention; ICER, Incremental Cost-Effectiveness Ratio; NBI, Needs-Based Intervention; N/A, Not Applicable, OASIS, Outreach and Support in South
London; PAU, Practice as Usual; QALY, Quality-Adjusted Life-Year; RC, Routine Care; SC, Standard Care; SD, Standard Deviation; SPI, Specific Preventive Intervention; WTP, Willingness-to-Pay.
†Bootstrapped 95% CI of mean difference between treatment groups.
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2.4.6

Risk of Bias Assessment

The risk of bias scores from the CHEC checklist (Table 2.3) and ISPOR checklist
(Appendix C) varied across all six studies. The methodological quality of the included
economic evaluations was generally fair – four of the six included studies met at least
70% of the criteria in the CHEC checklist. The cost-effectiveness analyses performed
better on the CHEC checklist compared to the cost analyses, and this trend was similarly
seen in the trial-based studies compared to the model-based studies. Consistent
limitations across all assessments were the lack of studies examining costs at the societal
perspective, as well as a paucity of incremental analyses using ICERs. Discounting was
completed in three of the studies, though the rationale provided in the studies that did not
employ discounting (n=3) stated that the time horizon was too short. In terms of the
ISPOR checklist for model-based evaluations, three of the four studies met at least 70%
of the criteria. Nevertheless, it should be noted that the only study with a clear, formal
process for developing the model was the Markov model by Wijnen et al,81 as they had
an expert panel to assess model validity and additional supporting documentation.
Though there were moderate levels of bias across the model-based studies, a consistent
trend was the lack of transparent internal verification and external validation. Overall, the
risk of bias scores were similar between the CHEC and ISPOR checklists.
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Ising et al, 2017

Perez et al,80 2015

Wijnen et al,81 2019

+
+
+
+
+
+
–
+
+
+
+
+
+
+
–
+
–
–
+
+
–
+
–
+
+
+
+
+
+
+
–
–
+
+
+
–
–
+
+
+
–
+
–
–
–
–
+
–
–
+
+
+
+
+
+
+
+
+
–
+
+
+
+

Abbreviations: +, Yes; –, No; N/A, Not Applicable.

+
+
+
+
+
+
+
+
+
+
+
+

N/A N/A N/A N/A

+
+
+
+

–
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Are ethical and distributional issues discussed appropriately?

+
–
–
+
+
–
+

17
Does the article indicate that there is no potential conflict of interest
of study researcher(s) and funder(s)?

Does the study discuss the generalizability of the results to other
settings and patient/ client groups?

N/A N/A N/A N/A

16

Do the conclusions follow from the data reported?

N/A N/A N/A N/A

15

Are all important variables, whose values are uncertain,
appropriately subjected to sensitivity analysis?

Table 2.3 Summary of the Consensus on Health Economic Criteria (CHEC) risk of bias assessment74
Table 2. 3 Summary of the Consensus on Health Economic Criteria (CHEC) risk of bias assessment
No.
1
2 3
4
5
6
7
8 9
10
11
12
13 14

Are all future costs and outcomes discounted appropriately?

Is an incremental analysis of costs and outcomes of alternatives
performed?

Are outcomes valued appropriately?

Are all outcomes measured appropriately?

Are all important and relevant outcomes for each alternative
identified?

Are costs valued appropriately?

Ising et al, 2015

Are all costs measured appropriately in physical units?

79

Are all important and relevant costs for each alternative identified?

McCrone et al, 2013

Is the actual perspective chosen appropriate?

78

Is the chosen time horizon appropriate to include relevant costs and
consequences?

Valmaggia et al, 2009

Is the economic study design appropriate to the stated objective?

77

Is a well-defined research question posed in answerable form?

Phillips et al,76 2009

Are competing alternatives clearly described?

Author, Year
Is the study population clearly described?

31

18
19

+
+
+
+
+
+
+
+
–
–
+
+
+
+
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2.5

Discussion

In this systematic review of the literature on economic evaluations of interventions for
people identified as UHR for psychosis, we found evidence to suggest that, from a health
system perspective, UHR programs may be cost-effective compared to routine care.
Although sensitivity analyses suggested that the cost-effectiveness findings were robust
to changes in the parameters, evidence for cost savings were more equivocal. The cost
analysis conducted by Valmaggia et al77 showed evidence of cost savings over 24
months. However, Phillips et al76 found that over 36 months, the total costs of the UHR
program were not significantly different from the comparison intervention – though it
was noted that the study was not suitably powered to make definitive conclusions. The
short-term costs at six months returned similarly conflicting results. Phillips et al76 found
the outpatient costs for their UHR program to be more expensive than the alternative,
whereas McCrone et al78 found UHR programs to be superior in cost savings, and was the
only cost study to support UHR programs completely. However, McCrone et al78 only
examined one reported time point (six months), and sensitivity analyses in both cost
studies conducted by McCrone et al78 and Valmaggia et al77 revealed instances where
UHR programs were not cost saving. Overall, all the above observations were derived
from a small number of cost analyses (n=3) and cost-effectiveness analyses (n=2) from
different health systems – the UK, the Netherlands, and Australia – and may not be
generalizable across settings. More specifically, data used in the cost-effectiveness
analyses originated from the same Dutch trial (EDIE-NL), which may explain the similar
results across the studies. Although the cost-effectiveness studies generally adhered to
best practices for economic evaluations, the risk of bias assessments found moderate
levels of bias across the cost studies. Finally, though there is value in cost analyses, it is
preferable that studies be conducted as full economic evaluations (cost-effectiveness,
cost-benefit, or cost-utility analyses) comparing UHR programs to routine care to better
inform decision-making.82
Overall, caution must be exercised when interpreting these findings due to several
limitations of the included studies. First, future economic evaluations would benefit from
consistent valuation of outcomes and long-term assessments of UHR programs. The
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current review found that there were only two studies that used QALYs, which is the
preferred outcome measure in health economic evaluations.82 Only one study, a costeffectiveness study by Wijnen et al,81 examined a ten-year time horizon. The short time
horizons, equivocal results on cost savings, and prior research suggesting UHR programs
are effective only during the program’s duration,70 warrant the need for more economic
evaluations examining long-term cost-effectiveness. Although, the risk for transition to
psychosis is the most prominent within two years of entry into an UHR clinic, there is
still a risk of transition for up to ten years,83 further highlighting the need for longer time
horizons. Another limitation is the small sample size of most included studies, which
varied among trial-based evaluations (n=59 to 196). Smaller studies may have large
standard deviations and results can be influenced by outliers. Although we could not
assess outliers based on published results, Phillips et al76 (n=59) mentioned that one or
two participants in the comparison intervention had higher than expected outpatient costs
during the 12 to 36 month follow-up. Another limitation to consider is that the costing
perspective across all studies was generally a health system perspective. This means that
additional costs associated with psychosis that are relevant to the societal perspective,
such as encounters with the criminal justice system,84 are not included. In addition, UHR
programs and routine care are not standardized across different countries and contexts,
thereby limiting our ability to comment on which interventions are more cost-effective
within the umbrella of UHR programs. One of the included studies did not conduct a
sensitivity analysis, and in instances where sensitivity analyses were done, they varied
among the individual studies. Therefore, in order to generalize these findings, economic
evaluations need to be done using consistent and robust methodology, and
generalizability across health care jurisdictions should be explicitly assessed.
A similar systematic review by Aceituno et al31 assessed the cost-effectiveness of early
intervention programs for psychosis, but was limited to cost-effectiveness studies, and
did not exclusively examine UHR programs. As a result, their review identified only two
of our included studies.20,79,80 Similar to our findings, their review found early psychosis
intervention services to be potentially cost-effective, though firm conclusions could not
be drawn due to the high degree of heterogeneity and variations in methodology across
the economic evaluations. The previously stated methodological limitations contributed
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to this heterogeneity, in addition to differences in outcome valuation, and differences in
the countries and study populations. They note that it was unclear whether these
differences were due to methodological or reporting errors. An older systematic review
by Amos et al66 examined recent-onset psychosis and UHR populations, including both
partial and full economic evaluations. They only identified two out of six studies in the
current review.76,77 Though the study by Valmaggia et al77 was praised for a thorough
sensitivity analysis and Phillips et al76 was similarly acknowledged for sourcing costs
from RCT data believed to have low evidence of bias, final conclusions echoed
sentiments similar to Aceituno et al31 and the current review. In line with the current
review, Aceituno et al31 and Amos et al66 call for future studies to adhere to consistent,
transparent guidelines available for economic evaluations.

2.5.1

Limitations

There are a number of limitations to this systematic review. It was not possible to conduct
a meta-analysis due to several key differences across the studies. Examples included the
types of economic evaluations conducted and the types of effectiveness measures used.
These differences affected our ability to draw firm conclusions on identified trends. We
limited our search to English language publications, and as a result, there may be
publication bias, as negative studies are more frequently published in non-English
language journals.85 We made efforts to retrieve data from grey literature sources to
mitigate the effects of publication bias, whereby economic evaluations supporting the
cost-effectiveness of UHR programs are more likely to be published. However, there is
still a possibility that the trends we observed in this review may be due to this
phenomenon.

2.5.2

Implications for Future Research

UHR programs provide an essential service to people who may be distressed and
symptomatic18 and there is some evidence to suggest the cost-effectiveness of these
programs. There are a number of steps that may be taken to strengthen future research.
For instance, increasing the number of economic evaluations conducted alongside
prospective trials examining the long-term health outcomes of people at UHR for
psychosis would result in more comprehensive assessments of the economic value of
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UHR programs. In addition, incorporating information from other sectors, such as social
services or criminal justice, could enrich cost data so that it may better reflect the societal
costs. Finally, health outcomes that can be valued consistently and compared easily
across evaluations of different interventions may help inform decision making.

2.5.3

Conclusions

Our qualitative synthesis of economic evaluations of UHR programs suggests that
intervening in this population may offer value for money. Specifically, all included costeffectiveness studies supported the UHR programs, but only one cost analysis study
supported the cost savings of this program. Yet, caution must be taken when drawing
firm conclusions given that different health care systems were examined, QALYs were
used sparingly, and there was a limited number of cost-effectiveness studies based on
RCTs. Although the review suggests that UHR programs may be cost-effective, this
evidence should be interpreted in light of the heterogeneity of populations across studies
and the lack of consensus on what interventions should be offered through UHR
programs. Future economic evaluations of UHR programs would benefit from long-term
assessments of these services, consistent valuation of outcomes, standardization of UHR
programs across jurisdictions and contexts, and the inclusion of costs from the societal
perspective to better inform public decision-making.
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Chapter 3
3

Risk Stratification for Treatment Decisions in People at

Ultra-High Risk for Psychosis: A Cost-Effectiveness Analysis
3.1

Abstract

Aim: Current clinical practice at ultra-high risk (UHR) for psychosis clinics is to treat all
patients at risk of converting to first-episode psychosis (FEP), regardless of their level of
risk. Our objective was to evaluate the cost-effectiveness of using risk stratification for
treatment decisions in an UHR program, based on the probability of converting to FEP,
compared to the standard ‘treat all’ strategy. Methods: We developed a decision tree
followed by a Markov model to evaluate risk stratification for treatment decisions
compared to the standard ‘treat all’ practice in an UHR program. Health states included:
Not UHR, UHR (<20% risk and ≥20% risk of developing FEP based on the North
American Prodrome Longitudinal Study risk calculator), FEP, Remission, Post-FEP, and
Death. A Canadian health system perspective and 15-year time horizon was used.
Transition probabilities were informed predominantly by the published literature and cost
data were based on a Canadian UHR clinic. Robustness of the results were tested using
scenario and sensitivity analyses. Results: The incremental cost-effectiveness ratio
(ICER) for risk stratification, compared to treating all, was $15,466 per quality-adjusted
life-year (QALY) and lies in the southwest quadrant of a cost-effectiveness plane. This
implies that risk stratification is a cost-saving strategy (saving $1,193 per person) and has
a health opportunity cost of 0.077 QALYs. The decision to adopt or reject risk
stratification depends on the willingness-to-accept (WTA) threshold. Sensitivity analyses
suggest trends were generally consistent with the main results. Conclusions: Treatment
decisions based on risk stratification offers lower costs and lower QALYs relative to the
standard practice of treating all UHR patients. The ICER estimate suggests that the
standard ‘treat all’ strategy is likely to be cost-effective. Future studies could consider
how different treatment intensities based on conversion risk may impact outcomes and
cost-effectiveness.
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3.2 Introduction
Despite the relatively low prevalence of psychotic disorders, the global economic burden
of schizophrenia ranges between $94 million to $102 billion annually.12 Though cost
varies depending on the type of health care system, resource use, and other factors,
Canadian estimates approach the billions as well – a 2004 study estimated $4.83 billion
in productivity losses alone.12,13 In Canada, the high cost of psychotic disorders such as
schizophrenia can be partially explained by the higher rates of service use – particularly
high cost services such as the emergency department (ED), inpatient unit, and long-term
prescription medications – relative to mood, anxiety, and substance use disorders.86
Psychotic disorders typically emerge in adolescence and early adulthood, and manifest
symptoms that contribute to long-lasting negative outcomes, such as ongoing disability
and functional impairment, repeated hospitalizations, and unemployment.8,12,86 Thus,
there is a great need to attempt treatment strategies that aim to mitigate symptoms or
prevent the disorder entirely. An ideal clinical stage to target for such interventions is the
ultra-high risk (UHR) for psychosis state, which precedes the first episode of psychosis
(FEP), and is characterized by increasing subthreshold psychotic symptoms and a decline
in functioning.6,17 Early psychosis programs have aimed to provide treatment at the UHR
stage and have seen some success.7 One challenge to intervention in the UHR state is that
only a fraction of people will convert to full psychotic disorder,21 with estimates ranging
from 10% at six months to 37% over four years.40 Assessment tools, such as the
Structured Interview of Prodromal Syndromes (SIPS),36 are commonly used to identify
people who meet the UHR criteria.17,49 However, these tools may also identify people
with a very low probability of conversion, which may lead to treatment of people whose
symptoms are mild and transient or not clinically significant,42,46 and therefore limit the
resources available to treat more severe cases. In particular, although SIPS has a high
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sensitivity (96%), the low specificity (39%) will identify many who will not convert,
despite screening positive.60 With clinicians facing constant pressure to make treatment
decisions that minimize resource use and maximize health care benefits,87 and with finite
resources available, strategies are now being proposed that consider these factors in the
development of clinical practice guidelines.87,88
Psychosis prediction tools aim to quantify the level of risk for conversion to psychosis
within the UHR population.59 One such tool is the North American Prodrome
Longitudinal Study (NAPLS) risk calculator, which estimates the probability of
conversion to psychosis for people identified as UHR by SIPS.22 Published work exists
examining the conversion outcomes of people with different NAPLS risk scores22 and the
calculator has shown acceptable results in external validation studies.63–65 The NAPLS
calculator may help to optimize resource allocation through the adoption of a treatment
strategy based on risk stratification, whereby treatment of prodromal symptoms with an
aim of preventing conversion to FEP is limited to people at a sufficiently high risk to
convert to psychotic disorder. In the original NAPLS study, those with less than 20% risk
for conversion had a larger proportion of non-converters compared to converters, whereas
those above this risk class had far more converters compared to non-converters.22
Prioritizing UHR treatment to those more likely to convert to psychosis (≥20% risk) may
be potentially more cost-effective. To our knowledge, the NAPLS scores are currently
only being used for research purposes in Canada, but modeling the economic impact of
using these risk scores for treatment decisions may inform the potential utility of risk
stratification in this population.

3.2.1 Study Objectives
We sought to estimate the cost-effectiveness of using a risk stratification approach for
treatment decisions in a UHR program, based on the probability of conversion to
psychosis, compared to the standard ‘treat all’ strategy. The analysis was completed from
the Canadian health system perspective and assessed over a 15-year time horizon.
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3.3 Methods
This study followed the Consolidated Health Economic Evaluation Reporting Standards
(CHEERS) guidelines.89 The completed checklist can be found in Appendix E.

3.3.1 Model Structure
A decision analytical model was created in Microsoft Excel 2016 (Microsoft Corporation,
Redmond, WA, USA) examining the 15-year cost-effectiveness of a risk stratification for
UHR treatment strategy based on the NAPLS calculator (risk stratification), compared to
treating all people identified as UHR for psychosis (standard ‘treat all’ practice). We used
the Canadian health system perspective.
We developed a decision tree model and modified an existing Markov model (Figure
3.1). The cohort began in the decision tree (one-year time horizon) before entering the
Markov model (14-year time horizon with an annual cycle) and consisted of 1000 UHR
patients identified using the SIPS interview. We used a 15-year time horizon because
recent estimates suggest that conversion to psychosis can occur up to 15 years after
baseline assessments.90 The time horizon was also sufficient enough to ensure that most
people in the model had left the UHR states at the end of the 15 years – less than 2% of
the cohort remained in both UHR states (<20% UHR and >20% UHR combined) and in
both treatment arms. We assumed that people in the cohort were 19 years of age based on
the mean age of the sample in the original NAPLS calculator study.22 For the risk
stratification arm of our model, people who scored <20% on the NAPLS calculator
received an annual follow-up with a psychiatrist (i.e. annual risk assessment), but no
further treatment for two years, whereas those who scored ≥20% on the calculator
received two years of treatment through the UHR program (i.e. UHR treatment). In the
standard ‘treat all’ practice arm of our model, two years of UHR treatment was provided
to everyone, regardless of their NAPLS risk score. Those who were treated followed a
two-year treatment plan because it is the standard of care in Canadian UHR programs.19
We assumed that people transitioned to general mental health services after two-years of
UHR treatment; however, if conversion to psychosis occurred during the first two years
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of UHR treatment or at any point in the long-term follow-up, these people would receive
treatment for psychosis from an early psychosis intervention program.
After one year in the decision tree (where people either converted to FEP or stayed
UHR), the cohort entered the Markov model. The Markov model was based on PsyMod –
a 2019 model created by Wijnen and colleagues81 that was used to evaluate the costeffectiveness of cognitive behavioral therapy (CBT) compared to treatment as usual in a
Dutch UHR population. PsyMod did not evaluate risk stratification for treatment
decisions, but instead assumed that everyone in the UHR state would be treated.20,81 We
modified PsyMod to evaluate the longer-term cost and health consequences of the risk
stratification treatment approach. The PsyMod model was obtained from the authors, who
also provided advice on model parameters. The original model structure and parameter
values are publicly available and described elsewhere.81 The novel aspects of our analysis
included: the addition of a decision tree model that stratified UHR patients by risk, the
use of Canadian costs and probabilities (where available), and the shift in focus from the
evaluation of treatment effectiveness for the UHR population to treatment allocation
strategies.
To evaluate longer-term costs and outcomes, participants entered the Markov model in
one of the three states from the decision tree: FEP, <20% UHR (those assessed as <20%
risk for psychosis but did not convert to FEP) and ≥20% UHR (those assessed as ≥20%
risk for psychosis but did not convert to FEP). In subsequent cycles, participants would
either stay in the same state or transition to one of the following Markov states: ‘Not
UHR’ (those who no longer meet the criteria for the UHR state), Remission (total
remission from FEP based on consensus criteria from Andreason and colleagues),91 PostFEP (incomplete remission following FEP), or Death. Transition to post-FEP or
remission was only possible after having experienced FEP. Transition to ‘Not UHR’ was
only possible after being either <20% UHR or ≥20% UHR. Figure 3.1 shows the decision
tree with the modified Markov model and the state-transition diagram for the Markov
model.
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A

B

Figure 3. 1 The (A) decision tree and Markov model and (B) state-transition diagram.

Figure 3.1 The (A) decision tree and Markov model and (B) state-transition diagram.
The Markov model is adapted from ‘PsyMod’ in the study by Wijnen and collegues81
The numbers in the decision tree and Markov model correspond to the ‘Transition Number’ in Table 3.1.
‘M’ represents the Markov node. UHR participants begin in the (A) decision tree for one year, then enter
the Markov model in the following year (M1-M3). In the third year and until the end of the Markov time
horizon (14 years total), people may enter the remaining states (M1-M7). The Markov model has a oneyear cycle, so people move between states once a year. The health states are defined as: <20% ultra-high
risk for psychosis (<20% UHR), ≥20% ultra-high risk for psychosis (≥20% UHR), recovery from the ultrahigh risk state (Not UHR), First-episode psychosis (FEP), Remission from FEP (Remission), incomplete
remission from FEP (Post-FEP), and Death.
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3.3.2 Transition Probabilities
Transition probabilities for the decision tree and Markov model were derived
predominately from the NAPLS literature. Where parameter data could not be obtained
from the NAPLS study, Canadian values – where possible – were instead retrieved from
a focused search strategy in MEDLINE (Appendix F) and by handsearching references.
The transition probabilities for conversion to the FEP state differed based on whether one
received treatment for UHR or not. To specify, the latter group only received an annual
risk assessment with the NAPLS calculator. For those receiving UHR treatment, the
transition probability to FEP was based on the NAPLS study in which participants were
given risk scores and received a mix of medication or therapy.22 Since the NAPLS study
reported two-year transition probabilities, we converted them to annual probabilities to
align with the model cycle length. Annual probabilities were estimated by first converting
the two-year probabilities to an instantaneous event rate, and then to a one-year transition
probability. The following formulas were used and assumed that the events had a
constant rate:
𝑟 =

− [ln (1 − 𝑝)]
𝑡

𝑝 = 1 − exp {−𝑟𝑡}
where r is the rate, p is the probability, and t is the time period of interest.92
For individuals not receiving UHR treatment, the annual transition probability for
conversion to FEP was calculated by adjusting the probability in the UHR treatment
group. This adjustment is based on a previous meta-analysis by van der Gaag and
collegues.93 The meta-analysis reported a relative risk (RR) of 0.463 (95% CI = 0.33–
0.64) at 12 months to convert to psychosis for those enrolled in early psychosis
intervention (generally medication and CBT) compared to a less intensive, control
condition (generally placebo and monitoring or placebo and supportive therapy).93 The
conversion risk in the ‘not treated’ group was calculated by dividing the probability of the
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treated group to convert to psychosis by the RR (Appendix G, Section G.1.1). It has also
been found that, in the long-term, annual probabilities to convert to psychosis decreases
within the UHR population.90,93,94 There is little known about how this applies to
subpopulations of the UHR group that are risk-stratified by NAPLS scores. Therefore, the
conservative long-term assumption was made that the risk to convert to psychosis
remained unchanged over time (3+ years) in both groups. Details on the probabilities to
convert to psychosis in both treatment arms are available in Table 3.1, but are also
available in the Appendix (Appendix G, Table G.1). Sensitivity analyses on how results
would change with different values for conversion to psychosis are presented in the
Appendix (Appendix G, Figure G.1), and are presented in the results (see Section 3.4.4).
Age-dependent mortality probabilities for the general population were derived from
Statistics Canada.95 There is evidence of higher mortality among those experiencing
psychotic disorders.96 The additional mortality may be partially attributed to increased
risk of suicide, but there are also factors such as physical comorbidities, and
antipsychotic medication use to consider.96–99 Therefore, to provide mortality estimates
for those in the FEP and Post-FEP states, we applied age-specific standardized mortality
ratios from an Ontario FEP population (in press)100 to the general population mortality
probabilities (Appendix G, Table G.2). The focused MEDLINE search did not return any
Canadian mortality probabilities for the UHR states. Therefore, the general population
mortality was used on the UHR groups. There is also past precedent of using general
mortality estimates for the UHR group in the original PsyMod publication.81 The
transition probabilities used in the model and their sources can be found in Table 3.1.
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Table 3.1 Annual transition probabilities for the decision tree and Markov model
Table 3. 1 Annual transition probabilities for the decision tree and Markov model
Transition
State Transition
Parameter
Distribution
Number
Decision Tree
Risk Stratification Treatment Strategy
1
Proportion who score ≥20%
0.349
Beta
upon entry into the UHR clinic
2
Year 1: <20% UHR State to FEP
0.077
Lognormal
State (Annual Risk Assessment)
≥20% UHR State to FEP State
0.148
Beta
(UHR Treatment)
Standard ‘Treat All’ Strategy
4
Proportion who score ≥20%
0.349
Beta
upon entry into the UHR clinic
5
Year 1: <20% UHR State to FEP
0.036
Beta
State (UHR Treatment)
6
≥20% UHR State to FEP State
0.148
Beta
(UHR Treatment)
Markov Model
Risk Stratification Treatment Strategy & Standard ‘Treat All’ Strategy
2
Year 2: <20% UHR State to FEP
0.056
Estimate‡
State (Annual Risk Assessment)
2
Year 3+: <20% UHR State to
0.036
Beta
FEP State (Annual Risk
Assessment)
5
Year 2+: <20% UHR State to
0.036
Beta
FEP State (UHR Treatment)
7
<20% UHR State to Not UHR
0.184
Beta
State
8
<20% UHR State to FEP State
0.036
Beta
(General Mental Health
Services)
3

0.184

Beta

10

≥20% UHR State to Not UHR
State
≥20% UHR State to FEP State
(General Mental Health
Services)

0.148

Beta

11

FEP State to Post-FEP State

0.678

Dirichlet

12

FEP State to Remission State

0.300

Dirichlet

13

Remission State to Post-FEP
State
Post-FEP State to Remission
State

0.496

Dirichlet

0.350

Dirichlet

9

14

Source†

Cannon et al,22
2016
Cannon et al,22
2016
& van der Gaag
et al,93 2013
Cannon et al,22
2016
Cannon et al,22
2016
Cannon et al,22
2016
Cannon et al,22
2016

Estimate
Estimate
Cannon et al,22
2016
Addington et
al,101 2019
Cannon et al,22
2016
& van der Gaag
et al,93 2013
Addington et
al,101 2019
Cannon et al,22
2016
& van der Gaag
et al,93 2013
Jordan et al,102
2014
Jordan et al,102
2014
Wijnen et al,81
2019
Wijnen et al,81
2019

Abbreviations: FEP, First Episode Psychosis; UHR, Ultra-High Risk.
Note that mortality is not included in this table because it is an age-dependent transition probability. In addition, the probability of
staying in the same state (ex. FEP to FEP) was not included in this table because it is always equal to “1- (all other probabilities)”
†
Assumptions for the sources can be found in Appendix G.
‡
The distribution is the average between the distribution from Transition Number 2 (Year 1) and Transition Number 2 (Year 3).
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3.3.3 Service Use
Information on standard of UHR care and service use was based on expert opinion from
the PROdromal Symptoms of Psychosis – Early identifiCation and Treatment
(PROSPECT) clinic in London, Ontario and generally followed the Canadian UHR
treatment guidelines (Table 3.2).49,103 The risk stratification treatment strategy provided
an annual risk assessment to those under the risk score cutoff (<20% risk to convert to
FEP). Annual risk assessment involved an annual one-hour session with a psychiatrist per
person. In this session, the psychiatrist would use the NAPLS calculator to reassess the
predicted risk score to convert to FEP. People with scores equal to or above the risk
cutoff (≥20% risk to convert to FEP), and everyone in the standard ‘treat all’ strategy,
would receive UHR treatment. UHR treatment involved case monitoring by a nurse,
visits with a psychiatrist as needed, psychotherapy by a psychologist, vocational services
by a counsellor, and antidepressant medication prescribed by a psychiatrist. All services
were provided as individual sessions, with the exception of psychotherapy, which was
provided in groups of ten. We assumed 12 one-hour sessions annually for case
monitoring and psychotherapy, sessions annually with a psychiatrist as needed, and four
one-hour sessions annually with vocational support services. We also assumed that UHR
patients would be prescribed fluoxetine (40 mg/day). This intensive UHR treatment
protocol was provided for two years, at which point, patients would then receive care
from general mental health services, provided that they did not convert to psychosis and
require support from an FEP program. In these general mental health care services,
people who were UHR and had risk scores at or above the cutoff received out-patient
support from a psychiatrist, whereas those below this cutoff received care from a family
physician. Finally, patients who recovered from the UHR state saw a psychiatrist four
times a year. Table 3.2 provides further information on sessions and duration.
Details regarding FEP service use was obtained from expert opinion from the
PROSPECT clinic, unless otherwise specified. Specifically, people who converted to
FEP were assumed to receive the same ‘UHR treatment’ strategy outlined above in the
context of an early psychosis intervention program, but were additionally prescribed
antipsychotic medication (risperidone, 4 mg/day) or antipsychotic injections, and had
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their lipid and glucose levels monitored biannually. Finally, those in remission from FEP
received eight sessions annually with a psychiatrist.
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Table 3.2 Service use and cost of services
Table 3. 2 Service use and cost of services
Service
Service
Provider

NAPLS Assessment
Equipment Cost of
N/A
NAPLS Calculator
Consultation Using
Psychiatrist
NAPLS Risk
Calculator
Active Case Management
UHR, FEP, and Post-FEP
Case Monitoring
RPN
Visits with a
Psychiatrist
Psychiatrist
Psychotherapy (ABC- Psychologist
Coping Skills Group)
Vocational Support
Counsellor
FEP and Post-FEP
Metabolic Monitoring
N/A
(Glucose and Lipid
Levels)
Pharmacotherapy
UHR and 1/3 of FEP and Post-FEP
Depression
N/A
Medication –
Fluoxetine 40 mg/day
1/2 FEP and Post-FEP
Antipsychotic
N/A
Medication –
Risperidone 4 mg/day

Annual
Salary
(Median)

Unit cost ($)

Annual
Mean
Cost ($)

Source†

N/A

N/A

0.00

0.00

https://riskcalc.org/napls/

1

1

FFS

216

216

Ontario SOB – (pg. A155 &
A157)

12
8

1
0.5

$56,000
FFS

34
87

405
695

Calculated from salary

Patients
per
Session

Annual
Frequency
of Service

Length
of each
session
(hours)

N/A

N/A

1

1
1
10

12

1

$110,500

67

80

Ontario SOB – (pg. A162)
Calculated from salary

1

4

1

$46,000

28

111

Calculated from salary

1

2

N/A

FFS

39

77

Ontario SOB – (pg. J68 and
J64)

1

365

N/A

N/A

20 mg = 0.331
(x2 pills)

242

Ontario drug formulary
(https://www.formulary.healt
h.gov.on.ca/formulary/)

1

365

N/A

N/A

2

746

Ontario drug formulary
(https://www.formulary.healt
h.gov.on.ca/formulary/)
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1/2 FEP
Antipsychotic
N/A
1
Injection –
Paliperidone palmitate
(Invega Sustenna)
150mg/month
Consultations for UHR and FEP Prescriptions
Initial Consultation
Psychiatrist 1

9

N/A

N/A

636

2861

Ontario drug formulary
(https://www.formulary.healt
h.gov.on.ca/formulary/)

1

1

FFS

216

216

Repeat Consultation
Psychiatrist
Injection Nurse (FEP)
RPN
General Mental Health Services
<20% UHR
Pharmacotherapy
GP
offered by a GP
≥20% UHR
Referral by a GP
GP
Initial Consultation for Psychiatrist
Pharmacotherapy
Prescription
Repeat Consultation
Psychiatrist
Not UHR
Initial Consultation
Psychiatrist

1
1

4
9

0.5
0.5

FFS
$56,000

87
34

347
152

Ontario SOB – (pg. A155 &
A157)
Ontario SOB – (pg. A162)
Calculated from salary

1

1

0.5

FFS

68

68

Ontario SOB – (pg. A19)

1
1

1
1

0.5
1

FFS
FFS

68
216

68
216

Ontario SOB – (pg. A19)
Ontario SOB - (pg. A155 &
A157)

1

1

0.5

FFS

87

87

Ontario SOB – (pg. A162)

1

1

1

FFS

216

216

Repeat Consultation
Remission
Initial Consultation

Psychiatrist

1

4

0.5

FFS

87

347

Ontario SOB – (pg. A155 &
A157)
Ontario SOB – (pg. A162)

Psychiatrist

1

1

1

FFS

216

216

Repeat Consultation

Psychiatrist

1

8

0.5

FFS

87

695

Ontario SOB – (pg. A155 &
A157)
Ontario SOB – (pg. A162)

Abbreviations: ABC, Adversity Belief Consequence; FEP, First Episode Psychosis; FFS, Fee-for-service; GP, General Practitioner; NAPLS, North American Prodrome Longitudinal Study; RPN,
Registered Practical Nurse; SOB, Schedule of Benefits; UHR, Ultra-High Risk.
†
Service use was assumed to be expert opinion from the London (PROSPECT) clinic unless otherwise specified.
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Hospitalizations and ED visits were included for the UHR, FEP, and Post-FEP states in
Table 3.3, with details on additional assumptions in the Appendix (Appendix G, Table
G.3). Service use for ED visits and hospitalizations were informed from the PROSPECT
clinic (L.P) or additional Canadian publications.16,104 Only some people (see Table 3.3,
“Proportion in State”) used these services. For ED visits and hospitalizations, the <20%
UHR group was assumed to use half the services of the ≥20% UHR group. Changes to
this assumption were addressed in a scenario analysis. Total annual costs for each person
(UHR or FEP) using ED services and hospitalization services were about $483 and
$9819, respectively. These values were derived from a 2016 Ontario study by de Oliveira
and colleagues, which estimated net costs for service use in individuals with chronic
schizophrenia.14 These annual costs may not accurately reflect the costs for people
identified as UHR or with FEP, but uncertainty was addressed using sensitivity analyses.
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Table 3.3 Service use and cost of hospitalization and the emergency department
Table 3. 3 Service use and cost of hospitalization and the emergency department

Service

Service Use
(Proportion
in State)†

Annual Cost
($) (per person
per Year)

0.122

483

<20% UHR

0.061

483

≥20% UHR

0.122

483

0.069

9819

<20% UHR

0.035

9819

≥20% UHR

0.069

9819

<20% UHR

0.122

483

≥20% UHR

0.245

483

FEP

0.141

483

Post-FEP

0.082

483

<20% UHR

0.069

9819

≥20% UHR

0.139

9819

FEP

0.144

9819

Post-FEP

0.057

9819

ED Visits
Risk Stratification
Strategy
<20% UHR and ≥20%
UHR
UHR Treatment Strategy

Hospitalizations
Risk Stratification
Strategy
<20% UHR and ≥20%
UHR
UHR Treatment Strategy

Sources

Service Use: Expert Opinion (L.P)
Cost: de Oliveira et al,14 2016
Service Use: Expert Opinion (L.P)
Cost: de Oliveira et al,14 2016
Service Use: Expert Opinion (L.P)
Cost: de Oliveira et al,14 2016

Service Use: Expert Opinion (L.P)
Cost: de Oliveira et al,14 2016
Service Use: Expert Opinion (L.P)
Cost: de Oliveira et al,14 2016
Service Use: Expert Opinion (L.P)
Cost: de Oliveira et al,14 2016

General Mental Health Services
ED Visits
Service Use: Estimation
Cost: de Oliveira et al,14 2016
Service Use: Anderson et al,104 2018
Cost: de Oliveira et al,14 2016
Service Use: Anderson et al,16 2018
Cost: de Oliveira et al,14 2016
Service Use: Anderson et al,16 2018
Cost: de Oliveira et al,14 2016

Hospitalizations
Service Use: Estimation
Cost: de Oliveira et al,14 2016
Service Use: Anderson et al,104 2018
Cost: de Oliveira et al,14 2016
Service Use: Anderson et al,16 2018
Cost: de Oliveira et al,14 2016
Service Use: Anderson et al,16 2018
Cost: de Oliveira et al,14 2016

Abbreviations: FEP, First Episode Psychosis; UHR, Ultra-High Risk.
†
This refers to the proportion of people in the indicated state and strategy who use the indicated service.
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3.3.4 Costs
The costing perspective of this model was the health system perspective (Ontario
Ministry of Health and Long-Term Care). Total costs were calculated by determining the
product of unit costs and service use (Table 3.2). Unit costs were retrieved from the 2020
Ontario Schedule of Benefits for physicians.105 For nonphysicians, their applied hourly
salary was used as a proxy for unit costs, similar to methods used elsewhere in the
Canadian literature.106 Additional details on the assumptions for costs can be found in
Appendix G (see Section G.3). For those below the cutoff score in the risk stratification
treatment strategy, there were no costs associated with acquisition of the NAPLS
calculator because it is freely accessible online at https://riskcalc.org/napls/, but
assessment by a psychiatrist to attain a risk score had an associated fee ($216).
The annual cost for UHR treatment was estimated to be $2,312 per person. In the
standard ‘treat all’ arm, the cost of risk screening using NAPLS was excluded ($2,096).
Both cost and outcomes were discounted at an annual rate of 1.5%, as per the Canadian
Agency for Drugs and Technologies in Health (CADTH) guidelines.107 No baseline costs
were included, as it was assumed that because the participants were young, they were
unlikely to have previous instances of significant health care service consumption – this
rationale has also been used in other cost-effectiveness analyses on the UHR
population.20,79 Costs for each state can be found in Table 3.4.

3.3.5 Health Outcomes
Quality-adjusted life-years (QALYs) were used as the effectiveness measure – they are
derived using a measure of the quality of life in a given health state multiplied by the
length of time in that state.73 The quality of life is usually represented by utility values: a
preference weight scaled between zero (death) to one (perfect health).73 We searched for
Canadian quality-of-life values relevant to our model, but none were found. As a result,
most utilities were derived from a Dutch cost-effectiveness study using the PsyMod
model.20,81 This study used the 3-level version of the EQ-5D (EQ-5D-3L) instrument,
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with UK tariffs to value health states.20 For the purposes of the current study, we assumed
that these utilities were generalizable to the Canadian population (Table 3.4).
While most utilities were retrieved from PsyMod, utilities for the UHR states (<20%
UHR and ≥20% UHR) and the Remission state were estimated instead. Given that there
is evidence that the risk to convert is influenced by prodromal symptom severity, decline
in social functioning, and verbal learning and memory scores,22 we assumed that the
utility values for the <20% UHR state and ≥20% UHR state would differ – those with a
lower risk for conversion would have a higher utility value than those at a higher risk for
conversion. Our focused MEDLINE search did not return relevant values for these two
UHR state utilities. Therefore, the <20% UHR state utility was estimated by averaging
the utilities between the ‘Not UHR’ state and the UHR state from the original PsyMod
publication.81 Similarly, the average of the UHR state and the FEP state utilities was
calculated to estimate the ≥20% UHR state utility (see Appendix G, Section G.4).
Sensitivity analysis was performed to determine how our main results would change in a
scenario where both UHR state utilities had the same value from the original PsyMod
publication (0.640).81 The results are presented in Appendix G (Figure G.1). In the
original PsyMod publication, the ‘Not UHR’ state utility and Remission state utility were
the same. In order to establish rank ordering for the sensitivity analysis – to account for
inappropriate iterations where a ‘better’ health state (such as UHR) had lower utilities
than another (such as FEP) – the Remission state utility was modified from the original
PsyMod publication.81 Based on clinical opinion (L.P), the Remission state utility was
estimated to be closer to the <20% UHR state utility than the ‘Not UHR’ state. This is
because those in remission from FEP may experience more cognitive difficulties and
social stigma than those in the ‘Not UHR’ state. Sensitivity analysis was completed on
this parameter to assess its influence on the main results. For the Post-FEP state utility,
we used a UK utility value for moderately functioning outpatients with schizophrenia,
retrieved from the focused MEDLINE search.108,109
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Table 3.4 Cost and utility values for each health state
Table 3. 4 Cost and utility values for each health state
State
Cost
Cost ($) (SE)†
Distribution
Decision Tree
Risk Stratification
Treatment Strategy
<20% UHR (Annual Risk
952 (238)
Gamma
Assessment)
≥20% UHR (UHR Treatment)
3048 (762)
Gamma
Standard ‘Treat All’
Strategy
<20% UHR (UHR Treatment)
2469 (617)
Gamma
≥20% UHR (UHR Treatment)
2833 (708)
Gamma
Markov Model
Not UHR
563 (141)
Gamma
<20% UHR

1046 (261)

Gamma

≥20% UHR

2095 (524)

Gamma

FEP

6880 (1720)

Gamma

Post-FEP

2662 (666)

Gamma

Remission

910 (228)

Gamma

0

Gamma

Death

Utility
(95% CI)

Utility
Distribution

N/A‡

N/A

N/A‡

N/A

N/A‡
N/A‡

N/A
N/A

0.756
(0.729 – 0.782)
0.698
(0.669 – 0.726)
0.503
(0.472 – 0.534)
0.366
(0.336 – 0.396)
0.490
(0.459 – 0.521)
0.720
(0.692 – 0.747)
0

Beta
Beta
Beta
Beta
Beta
Beta
Beta

Abbreviations: CI, Confidence Interval; FEP, First Episode Psychosis; SE, Standard Error; UHR, Ultra-High Risk.
†
The SE is calculated similarly to a 2018 Ontario Health Technology Assessment, 106 where the SE was estimated to be ± 25% of the
mean cost.
‡
Note that QALYs are accrued in the decision tree, but only at the end of the year. This happens once someone converts (FEP), or
remains UHR (<20% UHR or ≥20% UHR). These utility values can be found in the Markov section of this table.

3.3.6 Base Case Analysis
In both the decision tree and Markov model, costs and associated QALYs were assigned
based on the state people were in. Given that events were expected to occur any time
throughout a cycle, a half-cycle correction was included, which provided an unbiased
assumption that the average event would occur in the middle of the cycle – instead of the
traditional assumption that movement to different health states occur at the end of each
cycle.110 The differences in cost and QALYs between the risk stratification and the
standard ‘treat all’ strategy was quantified using the incremental cost-effectiveness ratio
(ICER):73,92
𝐼𝐶𝐸𝑅 =

𝐶1 − 𝐶2
𝐸1 − 𝐸2
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where Ci and Ei are the cost (Canadian dollars) and effectiveness measures (QALY),
respectively.92 C1 and E1 refers to the risk stratification treatment strategy, whereas C2
and E2 refers to the standard ‘treat all’ strategy.

3.3.7 Sensitivity Analyses
Deterministic sensitivity analyses (DSA) and probabilistic sensitivity analyses (PSA)
were used to account for parameter uncertainty and assess the robustness of the model
base case results to changes in parameter values. DSA varies the parameter values to see
how the values affect the model results.73 A one-way DSA varies one parameter at a time,
whereas a multi-way analysis (one variation being a scenario analysis), would change
multiple parameters of interest.73 The PSA quantifies model uncertainty by providing
specific distributions for each parameter. Values can then be randomly sampled from
these distributions repeatedly to repeat the main analysis several times.73
DSAs were completed by varying: (i) the cost of the annual risk assessment if it were
provided by a trained psychologist instead of a psychiatrist ($67 instead of $215); (ii) the
prevalence of those at ≥20% risk (34.89% to 57.89%); and (iii) the state-specific utilities
values: <20% UHR (0.640 to 0.756), ≥20% UHR (0.366 to 0.640), Post-FEP (0.362 to
0.490), and Remission (0.720 to 0.756) state. Scenario analyses were also performed in
order to test whether cost-effectiveness would be substantially affected if the probability
to convert to psychosis increased in the second year of UHR treatment for those <20%
UHR in the ‘treat all’ strategy, rather than remaining unchanged in the expected two
years of treatment. This was done to demonstrate a scenario where treatment adherence
does not occur over the full course of treatment, which is common in treatments
involving medication.111 We also examined how increasing the use of the ED (from
12.2% to 24.5% of the cohort) and increased hospitalizations (from 6.9% to 13.9% of the
cohort) within the <20% UHR group affected results. This analysis was performed to
model uncertainty around the base case model assumption that those at <20% risk to
convert to FEP used half the ED and hospitalization services of those at ≥20% risk.
Evidence suggests that the <20% risk cutoff for treatment decision (used in the base case
analysis) is appropriate because so few convert,22 but we also evaluated the impact of
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other cutoff values for risk stratification to see if the increased risk for conversion (lower
QALYs) was suitably offset by the lower costs from the risk stratification treatment
strategy.
For the PSA, we completed 1000 iterations of the main analysis. Uncertainty for
transition probabilities and utilities were generally represented by beta distributions,
while the gamma distribution was used to vary costs. A rank order was enforced for the
utilities in the PSA to account for inappropriate iterations where a ‘better’ health state
(such as UHR) had lower utilities than another (such as FEP). The rationale for the
chosen range of values in the DSA, the probabilities used in the scenario analysis, and the
distributions for the PSA can be found in Appendix G (see Section G.5 to Section G.7).

3.4 Results
3.4.1 Base Case Analysis Results
The cost of the risk stratification treatment strategy to the health system was about
$16,459, with QALY gains of 8.331. In the standard ‘treat all’ practice, this was $17,652
with QALY gains of 8.408. Compared to treating all UHR patients (standard practice),
only treating those with ≥20% risk of conversion to FEP (risk stratification treatment
strategy) resulted in a cost reduction of $1,193 and a loss of 0.077 QALYs. The ICER for
risk stratification, compared to the standard ‘treat all’ strategy, was $15,466 per QALY
and lies in the southwest quadrant of a cost-effectiveness plane – this means that cost
savings can only occur in the risk stratification strategy if the health opportunity cost due
to lost QALYs are acceptable.

3.4.2 One-Way Deterministic Sensitivity Analysis Results
One-way DSAs were conducted to examine how the base case results would change if: (i)
the annual risk assessment was provided by a trained psychologist instead of a
psychiatrist; (ii) the prevalence of those at ≥20% risk increased; and (iii) health state
utilities for the <20% UHR state, ≥20% UHR state, Post-FEP, and Remission state were
varied (Figure 3.2). The ICERs for the risk stratification strategy (compared to the
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standard ‘treat all’ practice) were higher than the base case when the cost of the annual
risk assessment was decreased, when the utility value of the <20% UHR state was
reduced, and when the Remission state utility was increased. The ICERs were lower
when the prevalence of the people at ≥20% increased, when the <20% UHR state utility
was increased, and when the Post-FEP state utility was reduced. ICER values changed
only slightly by adjustments to the ≥20% UHR state utility parameter, as most people did
not spend significant time in this state, compared to the <20% UHR state. In all DSAs,
changes to model parameters resulted in a range of ICERs between $11,000 to $18,000
per QALY gained for the risk stratification strategy, compared to the standard ‘treat all’
treatment strategy. All ICERs remained in the southwest quadrant. Similarly, in all cases
in the DSA, the risk stratification treatment strategy continued to have lower costs than
the standard ‘treat all’ practice, but produced worse health outcomes. Generally, ICERs
that were larger than the base case ICER suggested that the incremental costs were large
(i.e., an increase in the difference in costs between the treatment strategies, suggesting
more cost savings in risk stratification) or incremental QALYs were small (i.e., a
decrease in the difference in QALYs between the treatment strategies, suggesting that
risk stratification had similar health outcomes to the standard ‘treat all’ strategy).
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Figure 3.2 Deterministic sensitivity analysis comparing the risk stratification treatment
strategy to the standard ‘treat all’ practice
Figure 3. 2 Deterministic sensitivity analysis comparing the risk stratification treatment strategy to the standard ‘treat all’ practice

The black bars indicate the base case results, while the grey bars indicate the different ICERs derived from
changes made to the: (A) cost of the NAPLS assessment; (B) prevalence of those who are ≥20% risk for
psychosis; (C) <20% UHR state utility; (D) ≥20% UHR state utility; (E) Post-FEP state utility; and (F)
Remission state utility.
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3.4.3 Scenario Analysis Results
The following scenarios were modeled to examine how they impacted the costeffectiveness results: (i) UHR treatment non-adherence in the standard ‘treat all’ practice
group in the second year (treatment effectiveness in the first year only) (ii) an increase in
use of the ED and hospitalizations for those who were at <20% risk for psychosis to
equal the service use in the ≥20% risk group; and (iii) scenarios where different risk score
cutoff values for UHR treatment decision were employed.
First, a scenario was modelled where <20% UHR people in the standard ‘treat all’
strategy did not adhere to the full two-year UHR treatment plan. To model this scenario,
the probability to convert to psychosis within this group was increased in the second year
(Table 3.5). When modeling this scenario, the risk stratification strategy costs and
QALYs remained unaffected, but the standard ‘treat all’ strategy became more expensive
and returned worse outcomes (lower QALYs) compared to the base case results. As a
result, the ICER (southwest quadrant) for the risk stratification strategy compared to the
standard ‘treat all’ strategy – $25,199 per QALY gained – returned a higher value than
the base case results.
Table 3.5 Results of changes in adherence to UHR treatment in the standard ‘treat all’
strategy
Table 3. 5 Results of changes in adherence to UHR treatment in the standard ‘treat all’ strategy

Adherence Scenario

Base Case
(Full Adherence of
UHR Treatment)
No Adherence in
Second Year of UHR
Treatment†

Risk Stratification
Treatment
Cost ($) QALY
16,459
8.331

16,459

8.331

Standard ‘Treat
All’ Practice
Cost ($) QALY
17,652
8.408

17,817

8.385

Difference

ICER

Cost ($)
-1,193

QALY
-0.077

($)/QALY
15,466

-1,358

-0.054

25,199

†

This scenario models a situation where <20% risk people in the standard ‘treat all’ strategy do not adhere to the UHR treatment plan
in the second year, which is equivalent to a risk to convert to psychosis of 5.6% in the second year, instead of 3.6%.

Next, we modeled a scenario where ED and hospitalization services were increased in the
<20% UHR group and modified from the assumption of half the service use of the ≥20%
UHR group (Figure 3.3). While the QALYs remained unchanged, the difference in costs
between the strategies decreased, resulting in fewer cost savings from risk stratification.
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As a result, the ICER was $10,721 for the risk stratification strategy compared to the
standard ‘treat all’ strategy in the scenario where service use was identical in the two risk
groups. This value – in the southwest quadrant – was lower than the base case value. In
this scenario, the standard ‘treat all’ strategy remained relatively inexpensive for each
additional QALY.
Emergency Department and Hospitalization Use in
the <20% UHR Group

ICER ($/QALY)

17500

15000

12500

10000
50.0
62.5
75.0
87.5
100
Percentage of Service Use in the <20% UHR Group Compared to the
>20% UHR Group (%)

Figure 3.3 Incremental cost-effectiveness ratios comparing risk stratification to the
standard ‘treat all’ practice for changes in emergency department use and hospitalization
Figure 3. 3 Incremental cost-effectiveness ratios comparing risk stratification to the standard ‘treat all’ practice for changes in emergency department use and hospitalization

The black bars indicate the base case results, while the grey bars indicate the different ICERs derived from
changes in the percentage of service use in the <20% UHR group compared to the ≥20% UHR group.

Next, we investigated how changing the cut-off for UHR treatment decision in the risk
stratification strategy affected the results (see Appendix G, Table G.6 for probabilities to
convert at different risk levels). As the cutoff ranges increased – meaning that the
proportion of people untreated increased – the ICERs for the risk stratification strategy
decreased (Figure 3.4). This decline was due to the greater losses of QALYs in the risk
stratification strategy because some people did not receive UHR treatment and were
therefore more likely to convert to FEP. Once again, all ICERs would be in the southwest
quadrant of a cost-effectiveness plane.
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Scenario Analysis of Cutoffs for Treatment Decision in the Risk
Stratification Treatment Strategy

ICER ($/QALY gained)
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Risk Score Cutoff for UHR Individuals Receiving Annual Risk Assessments (%)

Figure 3.4 ICERs comparing the risk stratification treatment strategy to the standard
‘treat all’ strategy at different risk cutoff scores from the NAPLS calculator
Figure 3. 4 ICERs comparing the risk stratification treatment strategy to the standard ‘treat all’ strategy at different risk cutoff scores from the NAPLS calculator

The black bar indicates the base case results. The grey bars indicate the different ICERs for the risk
stratification strategy. Under the risk stratification treatment strategy, UHR people with scores under these
cutoff scores would receive the annual risk assessment, while those equal to or above these scores would
receive UHR treatment.

3.4.4 Probabilistic Sensitivity Analysis Results
A PSA was also conducted to account for parameter uncertainty and repeated the main
analysis over 1000 iterations (Figure 3.5). The PSA showed that: 86.9% of the time, the
risk stratification strategy had lower costs and produced lower QALYs when compared to
the standard ‘treat all’ strategy. These ICERs were found in the southwest quadrant of the
cost-effectiveness plane. The median ICER for the risk stratification strategy over 1000
iterations was about $15,260 per QALY.
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Cost-Effectiveness Plane of Risk Stratification Strategy Compared
to 'Treat All' Strategy
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Figure 3.5 Cost-effectiveness plane showing 1000 iterations of the main analysis
between the risk stratification treatment strategy and the standard ‘treat all’ practice
Figure 3. 5 Cost-effectiveness plane showing 1000 iterations of the main analysis between the risk stratification treatment strategy and the standard ‘treat all’ practice

The black point indicates the median QALY difference and cost difference, respectively, for the risk
stratification treatment strategy compared to the standard ‘treat all’ strategy.

3.5 Discussion
3.5.1 Summary of Findings
This analysis sought to estimate the cost-effectiveness of a risk stratification treatment
strategy compared to a standard ‘treat all’ strategy for people at UHR for psychosis from
the Canadian health system perspective. Our main findings suggest that the risk
stratification treatment strategy is less expensive than the standard ‘treat all’ strategy, but
returned lower health outcomes. The base case results suggest that treating all people who
present to the UHR program – irrespective of their risk to convert to psychosis – had a
small incremental cost for additional favorable outcomes (QALYs). For all sensitivity
analyses, ICERs (in the southwest quadrant) larger than the base case value ($15,466 per
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QALY gained) generally favored risk stratification more so than the standard ‘treat all’
strategy, but lower ICER values generally favored the standard ‘treat all’ strategy. More
specifically, changes in individual parameters in the DSA highlight the robustness of the
main findings, with ICERs ranging between $11,000 to $18,000 per QALY gained for the
risk stratification treatment strategy, compared to the standard ‘treat all’ strategy. Results
from the scenario analysis supported the main results as well. The treatment
nonadherence scenario returned a substantially higher ICER ($25,199) than the base case
results and demonstrated that the model is sensitive to changes in the proportion of
people converting to psychosis while in the UHR program. In the scenario where ED and
hospitalization use was increased in the <20% risk group to more closely resemble the
≥20% risk group, we saw fewer cost savings from risk stratification and therefore, lower
ICERs. In the final scenario, different cutoff scores for treatment decision were
examined. We saw a decline in the ICERs as the cutoff increased – in favor of the
standard ‘treat all’ strategy – largely due the fact that the risk stratification strategy would
return worse outcomes as more people were left untreated (i.e., there were a greater
number of conversions to psychosis and associated health system costs). Overall, the
scenario analysis showed that the risk stratification strategy would become a more
desirable strategy to adopt if: (i) the UHR treatment became less effective, resulting in a
greater number of conversions to psychosis in the standard ‘treat all’ strategy; (ii) those at
<20% risk used acute care services at a much lower frequency than the ≥20% risk group,
thereby further reducing costs for the risk stratification treatment strategy; and (iii) the
risk score cutoff for treatment decision remained low and subsequently reduced the
number of conversions in the risk stratification strategy. Finally, the PSA demonstrated
that the main findings were robust to changes – the risk stratification strategy was cost
saving and returned worse outcomes 86.9% of the time.

3.5.2 Discussion of the Findings
Our main findings demonstrated that risk stratification reduces costs, but returns worse
outcomes, and that the standard ‘treat all’ practice is the preferred strategy because it is
reasonably inexpensive to the health system to gain additional QALYs. The results
suggest that risk stratification is a cost saving strategy (with savings of $1,193 per
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person) and has a health opportunity cost of 0.077 QALYs. The ICER was $15,466 per
QALY and lies in the southwest quadrant of a cost-effectiveness plane. Therefore, the
decision to adopt or reject risk stratification depends on the willingness-to-accept (WTA)
threshold. Interventions in the field of psychosis with similar ICERs have been suggested
to have good value for money. For example, an Ontario study found that CBT for
psychosis provided by nonphysician therapists offered good value for money at $21,520
per QALY gained, relative to usual care.106 Even strategies with considerably higher
ICERs have been suggested to provide good value for money – internet-delivered CBT
for anxiety in Ontario, which had an ICER of $43,214 per QALY gained compared to
unguided therapy, is one such example.112 The risk stratification treatment strategy would
only be considered to be a reasonable alternative in instances where the cost to provide
treatment for all UHR patients is untenable – which may be a possibility because UHR
programs are costly113 – or if there is an alternate non-specialized form of care for low
risk people that provides similar outcomes as UHR programs. These general mental
health services do exist, but the field is still fairly nascent.114,115
The scenario analyses returned results that were generally expected, based on clinical
evidence. When modeling low program adherence, the higher ICER (southwest quadrant)
for risk stratification compared to the standard ‘treat all’ strategy ($25,199) suggested
that the model is sensitive to changes to the probability to convert to psychosis. In a realworld setting, low adherence to treatment – such as medication for schizophrenia111 – is
linked to many negative outcomes, including increased risk of relapse, remission, and
hospitalization.111,116 This directly increases costs, as evidenced in literature,117,118 and to
a lesser extent, our model of low program adherence. There is also evidence showing that
the UHR population is heterogeneous in terms of functioning and symptom severity,
which in turn impacts their long-term outcomes.119,120 Yet, there is a paucity of literature
available examining service use or treatment effectiveness differences between the risk
groups based on the NAPLS calculator.22 Therefore, the additional scenario analyses
completed in this thesis that tested the assumption of service use between different UHR
classes and the cost-effectiveness at different risk cutoffs were exploratory in nature, and
only served to support the robustness of the main results. More specifically, the scenario
analysis examining the different risk cutoffs likely underestimated costs at higher ranges,
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given that costs were only estimated for the perceived service use of people at <20% risk
for psychosis and ≥20% risk for psychosis. Therefore, costs were not adjusted for the
presumed increase in service use expected if people with higher risk scores went
untreated. This may explain why the ICERs were impacted more by changes in QALYs
between the two treatment strategies, rather than costs.
Overall, our results consistently showed – as evidenced in the PSA – that the risk
stratification strategy remained an incrementally low-cost strategy, compared to the
standard treat all’ strategy, but returned worse outcomes.

3.5.3 Model Limitations
Our model had several limitations. Most notably, we assumed that the NAPLS risk scores
remained static over time, meaning that people could not move between the two UHR
states. The Markov model examined the average outcomes of the cohort and could not
follow individual patients and their outcomes, unlike patient-level state-transition models,
such as microsimulations.107 Costs in the model were valued based on service use under
ideal conditions and expert opinion from the PROSPECT UHR clinic, implying that
patients would adhere to all aspects of the treatment, including antipsychotic medication
regimens, which are known to have low adherence.111 To address this limitation, efforts
were made to assess the impact of low adherence in sensitivity analyses. In addition,
hospitalization and ED unit costs were derived from a study examining the economic
burden of health service use in an Ontario population of people with chronic
schizophrenia,14 which may not accurately reflect the costs for people identified as UHR
or with FEP. However, we attempted to account for cost uncertainty – and uncertainty in
other parameters – by completing a PSA. We also recognize that the duration of
psychotic illness and other symptoms vary, and that a one-year cycle length (with utilities
lasting for one year) may not reflect variability in these health states adequately. Also,
resource use data (expert opinion) was mainly derived from one Canadian UHR clinic
with small sample sizes, which may not be representative of other clinics in Canada.
Mortality estimates for the UHR group were based on general population mortality
estimates, as seen in the original PsyMod publication.81 We recognize that those at UHR

66
for psychosis may have an increased risk for mortality compared to the general
population – attributed to suicide for example83 – but did not have adequate data to
inform this mortality parameter. Finally, studies examining the long-term outcomes of
UHR patients found that the annual risk to convert to psychosis declines over time.90,94
Although our model only considered a declining risk to convert to psychosis over three
years in the untreated group (with the probability to convert in the third year persisting
indefinitely), we found that the proportion of people who remained UHR at the end of the
15 years in the model (~2% of the modelled cohort) was similar to those who remained as
UHR in a long-term study of UHR people after 15 years (~1%).90 With the added
understanding that there is a paucity of data available on the long-term annual
probabilities to convert to psychosis within groups stratified by NAPLS risk scores, it
was determined that no further modification to the conversion probability would be done.

3.5.4 Implications for Future Research and Conclusions
This economic evaluation focused on risk stratification for treatment decision and was
informed by prespecified NAPLS score cutoffs. The NAPLS risk calculator may show
promise in informing treatment allocation in instances where the cost savings outweigh
negligible losses in QALYs. The difference in costs between the treatment strategies
were not very large, whereas, the difference in QALYs were small. In addition, there is
uncertainty in the parameters. Therefore, careful consideration must be made by decisionmakers in weighing the small benefits in costs with the uncertainty of the estimates and
other literature published in this field. In interpreting the ICER (southwest quadrant) from
this study, a WTA threshold would have to be considered as well to determine if there is
an amount of QALYs a decision-maker is willing to forego in favor of additional
resources (i.e. cost savings) that can be invested into other interventions or treatment
plans in the field that can offer more QALY gains elsewhere. Overall, caution must be
exercised when examining our findings as future research is needed.
Future research requires a more rigorous method of valuing costs for the different risk
classes. There is also a need for more Canadian data in community settings to determine
the sensitivity and specificity of this calculator. In addition, given that there is already
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evidence of different levels of conversion risk impacting long-term health outcomes of
UHR people,22,119,120 future research may benefit from clinical trials examining long-term
outcomes of risk stratification for treatment decision compared to a standard ‘treat all’
strategy. This may better inform transition probabilities for future economic evaluations
related to conversion risk and recovery among those not receiving the complete resourceintensive UHR treatment. Alternatively, future studies could also consider different
intensity treatments or personalized treatment plans based on these risk scores.

3.6 Conclusion
The risk stratification treatment strategy, where UHR treatment was only provided to
those who had a ≥20% NAPLS risk score, resulted in an ICER of $15,466 per QALY to
the Canadian health system, relative to treating all people at UHR for psychosis. This
ICER lies in the southwest quadrant of a cost-effectiveness plane, meaning that risk
stratification resulted in lower costs and lower QALYs compared to treating everyone
identified as UHR. The cost reduction from the risk stratification treatment strategy may
not be worth the loss in QALYs. More precise cost valuation methods are needed to
determine how much the health system would be saving by not providing resourceintensive, specialized UHR services to those with low risk of conversion to psychosis. A
decision would also have to be made regarding an acceptable quantity of QALYs that can
be foregone in order to reallocate finite resources towards more severe UHR cases – that
is the WTA.
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Chapter 4
4

Extended Discussion and Conclusion

In this chapter, the results of the systematic review and economic evaluation will be
summarized and synthesized. An extended discussion of the contributions to the literature
and a detailed description of study limitations will follow. Finally, future directions in the
field will be discussed.

4.1

Summary of Results

The overarching objective of this thesis was to examine the state of the literature on
economic evaluations of ultra-high risk (UHR) for psychosis programs, and to then use
the findings to inform a novel economic model for identifying and treating people in
UHR programs from the Canadian perspective. First, a systematic review was conducted
to summarize and evaluate the literature, which included a qualitative synthesis of all
economic evaluation studies examining the cost and cost-effectiveness of interventions
for people identified as UHR (Chapter 2).1 This chapter provided the context necessary
for the subsequent cost-effectiveness analysis, which evaluated the use of risk
stratification based on the probability of conversion to psychosis for treatment decisions
in a UHR program, compared to the standard ‘treat all’ practice (Chapter 3).
Of the partial (cost) and complete (cost-effectiveness) economic evaluations of UHR
programs included in our systematic review (n=6), all cost-effectiveness studies and one
cost analysis suggested that UHR programs were potentially cost-effective and cost
saving, respectively. Despite these results, there were limitations to the included studies,
including: inconsistent valuation of outcomes, cost perspectives limited to the health
system perspective, and heterogeneity in results that may be due to methodological or
reporting errors. Although there was some evidence suggesting that UHR programs are
cost-effective (Chapter 2),1 the absence of a firm consensus is mirrored in the lack of
high-quality evidence available to more definitively show that UHR interventions are
clinically effective (see Chapter 1).54 These observations contributed to the decision to
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examine risk stratification treatment strategies in our economic evaluation, rather than
focus on any particular intervention. Similarly, the systematic review also helped
summarize the limitations to prior studies that could potentially be addressed in the
economic evaluation completed for this thesis.
The main objective of the economic evaluation was to examine whether the costeffectiveness of UHR programs from the Canadian health system perspective was
impacted by the use of a risk stratification treatment strategy that provided treatment to
those at or above a 20% predicted risk of conversion to psychosis, relative to the standard
practice of treating all UHR patients. Risk scores were based on the North American
Prodrome Longitudinal Study (NAPLS) risk calculator.22 The NAPLS calculator provides
a percentage score of the predicted risk to convert to psychosis among people identified
as UHR, and is described in detail elsewhere.22 In the risk stratification treatment
strategy, those below the 20% risk cutoff would receive an annual risk assessment with
the NAPLS calculator to monitor risk levels. Those at or above the cutoff, as well as
those in the standard ‘treat all’ practice strategy, would receive UHR treatment (which
primarily consisted of active case management). Many sensitivity analyses were
completed to evaluate parameter uncertainty, in addition to scenario analyses – most
notable was an examination of how different cutoff scores for UHR treatment decisions
in the risk stratification strategy would affect the base case cost-effectiveness results. The
economic evaluation found that treating those at ≥20% risk to transition – and only
providing annual risk assessments for those at <20% risk for psychosis – resulted in
lower costs and lower QALYs compared to treating everyone identified as UHR.
Compared to the standard ‘treat all’ strategy, the incremental cost per QALY estimate for
only treating those at ≥20% risk to convert to psychosis was $15,466. The ICER was in
the southwest quadrant of the cost-effectiveness plane, implying that cost savings can
only be made if the health system decision-maker is willing to accept the health
opportunity cost due to lost QALYs. We concluded that interpretations of these results
must be carefully assessed due to limitations on two fronts: (i) the NAPLS calculator is
novel and is currently only used for research purposes (not clinical practice), which
therefore limits the available literature to inform the economic model; and (ii) there is a
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paucity of data on service use available at the different risk levels, which limits the ability
to accurately value costs to the health system.
Both the systematic review and the economic analysis highlight the need for more
economic evaluations on UHR programs. There is a high rate of service use among
people with psychosis,86 and with UHR programs increasingly available worldwide,19,50 it
is imperative that research in this field continues in order to determine whether UHR
programs prevent or delay the onset of a first psychotic episode (FEP), lower service use
costs, and improve patient outcomes.

4.2

Contributions to the Literature and Policy

Implications
Our systematic review (Chapter 2)1 contributes to the literature by providing an update to
the evidence base on both partial and complete economic evaluations exclusively focused
on UHR populations. Other systematic reviews of economic evaluations have examined
UHR programs, but have also included FEP programs. For example, a systematic review
from 2012 examined whether UHR programs are cost-saving in different health care
settings, but included both recent-onset psychosis and UHR populations.66 Similarly, a
2019 systematic review on early intervention for psychosis also included both UHR and
FEP populations.31 Our systematic review provides a more recent update to the evidence
base (March 2020) and uses a rigorous search strategy. In addition, grey literature
databases were also searched to potentially mitigate the effects of publication bias – a
phenomenon where negative studies may be missed by systematic reviews because they
are more likely to be published in other formats less likely to be accessed.85 Finally,
results from this systematic review suggest a need for more economic evaluation of UHR
programs, which are sentiments echoed in other published systematic reviews.31,66
Our economic evaluation (Chapter 3) is the first to consider a risk stratification approach
for treatment decision in UHR programs and the first to be done from the perspective of
the Canadian health care system. In addition, attempts were made to strengthen the
economic model by addressing the limitations of previous models identified by our
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systematic review. In particular, the systematic review concluded that future economic
evaluations would benefit from more consistent valuation of outcomes, longer-term
assessments of UHR programs, assessments of cost from the societal perspective, and the
use of transparent guidelines for economic evaluations. Our economic evaluation used the
Canadian Agency for Drugs and Technologies in Health (CADTH)-approved qualityadjusted life-year (QALY) as our effectiveness measure,107 we examined outcomes from
a fifteen-year time horizon, and we used the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) Checklist89 to report our findings transparently. Finally,
while we considered using costs from the societal perspective, this was not feasible due
to the lack of available data to inform parameters.
Completing economic evaluations using QALYs as an outcome measure has benefits.
QALYs provide both a measure of the quality and quantity of life73 and allow an easier
comparison between different interventions on different health outcomes.121,122 These
characteristics make QALYs highly desirable for policy makers when allocating
resources across different health sectors.121,122 Though this may be true, economic
evaluations are encouraged to be completed alongside clinical trials in order to make
informed mental health policy decisions.121 To the author’s knowledge, there are
currently no published clinical trials that have examined the use of risk stratification
treatment strategies in the UHR population, and the impact on resource use and
effectiveness. Therefore, the results from this thesis would not serve to imply the need for
policy change, but instead serve as an exploratory analysis to suggest the potential
benefits of prioritizing treatment to those with a higher risk of transitioning to psychotic
disorder. Future decision-making using the ICER from this study are subject to
uncertainty within the estimates (especially because of the small incremental differences
in costs and QALYs in the model), the paucity of literature in the field, and the need to
establish a suitable willingness-to-accept threshold.

4.3

Thesis Limitations

Although both the systematic review and economic evaluation make their own unique
contributions to literature, they are not without limitations.
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4.3.1

Limitations of the Systematic Review

It was not possible to complete a meta-analysis for the systematic review. This was
largely due to heterogeneity in study results, including: differences in the effectiveness
measures used and differences in the types of economic evaluations conducted. The
search strategy was also limited to English studies, which may introduce publication bias.

4.3.2

Limitations of the Economic Evaluation

As mentioned previously, the economic evaluation adds a unique Canadian perspective to
the literature on priority-based treatment using a novel risk calculator currently used for
research purposes, with hopes of future clinical use. This study provides a novel
contribution to the literature, but this novelty also presented challenges on several fronts.
In terms of our outcome data, it was challenging to find utilities from the Canadian
perspective relevant to the modified states of our Markov model, so the utilities used
predominantly relied on ones retrieved from a Dutch study.20,81 However, it is wellknown that utilities are hard to attain for specific populations, particularly in the field of
mental health.121,122 It is especially challenging to derive utilities from populations with
certain mental illnesses, as there may be differences in participants’ capacity to
understand or make judgements on utility-measuring activities, especially in more severe
manifestations of disorder or where there is significant cognitive impairment.122 Some
state utilities were also estimated based on assumptions, but any uncertainty was
addressed in extensive sensitivity analyses.
Another limitation is that our estimates for service utilization (expert opinion) assumed
that there would be 100% engagement in all aspects of the program. We would then be
underestimating the real-world costs associated with poor outcomes from program dropouts or low program adherence, although we completed a sensitivity analysis to assess the
latter. Similarly, while costs due to lost productivity are likely to be significant in patients
with psychosis,13 our own model did not examine a perspective that accounts for these
costs, namely the societal perspective. This limitation is consistent across most economic
evaluations examining UHR programs – our systematic review only found two studies
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conducted from a societal perspective.20,77 However, even when the societal perspective
was employed in the included studies, factors such as criminal justice costs or caregiving
were not included.77 As is the consensus from our systematic review, and from the
discussion of the original PsyMod publication,81 there is a paucity of data available to
properly value societal costs. In addition, although our model did not value the costs and
service use for the different risk levels in the scenario analysis, it is important to
remember that NAPLS is still being used for research purposes only. Consequently, there
is no published data available on service-related outcomes stratified by risk score in the
NAPLS cohort, such as presentations to the emergency department and psychiatric
hospitalizations.
We obtained our transition probabilities from the Canadian literature, where available,
however some transition probabilities originated from international sources. In addition,
though the risk to convert to psychosis could be derived for the groups receiving
treatment, the transition probabilities for untreated groups (those receiving annual risk
assessments) had to be estimated indirectly from other parameters.93 This is due to the
fact that most clinical trials have control groups that are treated,45 so literature is sparse
on the outcomes for people identified as UHR who remain untreated. Finally, not all
transition probabilities used in our economic model considered how these may vary
between those with different risk scores – for example, the mortality risk among those
with a risk score of <20% versus ≥20%.

4.3

Future Directions

People who access UHR programs tend to be distressed and are at a greater risk of longterm negative outcomes.18 Our risk stratification treatment strategy implies that those
below a certain cutoff may not require treatment from an UHR clinic, but it does not
mean that they are not in need of comprehensive mental health care. UHR programs are
highly specialized, and people identified as UHR who are experiencing milder symptoms
and have a low probability of transitioning to psychosis may be better suited for other
services or treatment regimens. Future studies could examine the effectiveness of
providing different intensities of treatment based on risk scores, or by shifting away from
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UHR programs toward youth mental health services that broaden the accessibility to
people who may not necessarily meet the UHR criteria.
To the author’s knowledge, there is currently no clinical evidence on the effectiveness of
risk stratification for treatment decision for people identified as UHR for psychosis, but
the interest in risk scores or risk stratification for treatment decision is not unique to this
field.123,124 There are examples of different assessment tools available to predict transition
risk,59 and there is evidence to suggest that people with lower predicted risk scores have
less severe symptoms.22 How this knowledge should translate to treatment planning for
the UHR population is a topic for future studies. Our economic model only presents one
potential scenario, and future studies may explore how different intensities of treatment
based on risk score may impact effectiveness and cost-effectiveness.
An alternative way to address the heterogeneity of symptoms and varying levels of
conversion risk among people accessing UHR programs is to provide services to a
broader population – that is, people in need of general mental health services. Doing so
may identify a greater number of help-seeking people who meet the UHR criteria. This
will lead to a shift towards a transdiagnostic approach – the rejection of single-diagnosis
classification in favor of a new classification system that considers disease
comorbidities.125 Efforts have been made to promote an alternative service model that
provides primary mental health care, including general mental health assessments and
treatment. Examples include the Headspace initiative in Australia114 and the Canadian
equivalent, ACCESS Open Minds.126 Headspace provides a broad point of entry for helpseeking distressed youth between the ages of 12 and 25.114 These centers tend to be less
diagnosis-driven, with more of a focus towards needs-based psychotherapeutic
techniques.114 Services like Headspace are still in their early stages, and to date, have
been shown to provide small to moderate improvements in patient health.115 Similarly,
information on the cost-effectiveness of Headspace services is still in its early stages.115
Whether future research moves towards risk stratification strategies for UHR treatment
decision in order to identify those most in need of specialized services, or towards
broadening the criteria to provide treatment for all youth regardless of clinical
presentation, it is clear that more work needs to be done.
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4.4

Conclusions

The main objectives of this thesis were to examine the state of the literature on economic
evaluations of UHR programs, then to use this knowledge to help inform an economic
model comparing the cost-effectiveness of a risk stratification treatment strategy to the
standard ‘treat all’ practice. Our findings suggest that there is potential value for money
in UHR programs, and that not treating a proportion of the cohort results in losses of
good health outcomes, despite a reduction in costs. Both studies highlight the paucity of
clinical and economic evidence on treatment for the UHR population. Understanding the
contributions that specialized programs, like UHR clinics, may have on lessening the
health burden of psychotic disorders is important for improving health outcomes of
people in need of additional support18 and for lessening the economic burden on the
health system.86
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Appendix A Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) checklist

Section/topic
TITLE
Title
ABSTRACT
Structured
summary
INTRODUCTION
Rationale
Objectives
METHODS
Protocol and
registration
Eligibility criteria

# Checklist item

Reported
on page #

1

Identify the report as a systematic review, meta-analysis, or both.

15

2

Provide a structured summary including, as applicable: background; objectives; data sources; study
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results;
limitations; conclusions and implications of key findings; systematic review registration number.

16

3
4

Describe the rationale for the review in the context of what is already known.
Provide an explicit statement of questions being addressed with reference to participants, interventions,
comparisons, outcomes, and study design (PICOS).

17-19
17-19

5

Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available,
provide registration information including registration number.
Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years
considered, language, publication status) used as criteria for eligibility, giving rationale.
Describe all information sources (e.g., databases with dates of coverage, contact with study authors to
identify additional studies) in the search and date last searched.
Present full electronic search strategy for at least one database, including any limits used, such that it
could be repeated.
State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if
applicable, included in the meta-analysis).
Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any
processes for obtaining and confirming data from investigators.
List and define all variables for which data were sought (e.g., PICOS, funding sources) and any
assumptions and simplifications made.
Describe methods used for assessing risk of bias of individual studies (including specification of whether
this was done at the study or outcome level), and how this information is to be used in any data synthesis.
State the principal summary measures (e.g., risk ratio, difference in means).

19

Describe the methods of handling data and combining results of studies, if done, including measures of
consistency (e.g., I2) for each meta-analysis.

21

6

Information
sources
Search

7

Study selection

9

Data collection
process
Data items

10

Risk of bias in
individual studies
Summary
measures
Synthesis of
results

12

8

11

13
14

19-20
19
19
19-21
20-21
20
20-21
21
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Section/topic

# Checklist item

Risk of bias
across studies
Additional
analyses
RESULTS
Study selection

15

Study
characteristics
Risk of bias
within studies
Results of
individual studies
Synthesis of
results
Risk of bias
across studies
Additional
analysis
DISCUSSION
Summary of
evidence
Limitations

18

Conclusions

26

FUNDING
Funding

27

Reported
on page #

Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias,
selective reporting within studies).
Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if
done, indicating which were pre-specified.

N/A

Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for
exclusions at each stage, ideally with a flow diagram.
For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up
period) and provide the citations.
Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).

21

For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
Present results of each meta-analysis done, including confidence intervals and measures of consistency.

21 & Figure
2.1
23 & Table
2.1
30 & Table
2.3
23-27 & Table
2.2
N/A

22

Present results of any assessment of risk of bias across studies (see Item 15).

N/A

23

Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see
Item 16]).

N/A

24

Summarize the main findings including the strength of evidence for each main outcome; consider their
relevance to key groups (e.g., healthcare providers, users, and policy makers).
Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete
retrieval of identified research, reporting bias).
Provide a general interpretation of the results in the context of other evidence, and implications for future
research.

32-34

Describe sources of funding for the systematic review and other support (e.g., supply of data); role of
funders for the systematic review.

35-36

16

17

19
20

25

N/A

34
34-35
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Appendix B Complete electronic and grey literature search strategy

Electronic Database Search strategy
The initial search strategy and results below are from inception to 9/23/2019. The updated search strategy
used the same search terms from 9/23/2019 to 3/09/2020.
Medline (Ovid)
1
2

3
4
5
6
7
8
9
10
11
12

exp Prodromal Symptoms/
(at risk mental state* or ARMS* or psychosis risk* or psychosis
prediction* or psychosis onset* or prodrom* or prodromal psychosis* or
high risk* or ultra-high risk* or ultra high risk* or UHR or CHR or clinical
high risk* or clinical-high risk* or high clinical risk* or referr* or help
seeking* or progression to first-episode psychosis*).ti,ab,tw.
1 or 2
exp cost-benefit analysis/
exp "Costs and Cost Analysis"/
(economic evaluation* or health economic* or cost-effectiveness* or costbenefit* or cost analysis*).ti,ab,tw.
4 or 5 or 6
exp Schizophrenia/
exp Psychotic Disorders/
(Psychosis or psychotic or schizophreni* or sever* mental ill* or sever*
mental disorder* or psychiatric crisis* or crises*).ti,ab,tw.
8 or 9 or 10
3 and 7 and 11

Results: 152

Embase (Ovid)
1
2

3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

exp prodromal symptom/
(at risk mental state* or ARMS* or psychosis risk* or psychosis
prediction* or psychosis onset* or prodrom* or prodromal psychosis* or
high risk* or ultra-high risk* or ultra high risk* or UHR or CHR or clinical
high risk* or clinical-high risk* or high clinical risk* or referr* or help
seeking* or progression to first-episode psychosis*).ti,ab,tw.
1 or 2
exp economic evaluation/
exp "cost benefit analysis"/
exp "cost minimization analysis"/
exp "cost utility analysis"/
exp "cost effectiveness analysis"/
exp health economics/
(economic evaluation* or health economic* or cost-effectiveness* or costbenefit* or cost analysis*).ti,ab,tw.
4 or 5 or 6 or 7 or 8 or 9 or 10
exp schizophrenia/
exp psychosis/
exp affective psychosis/
exp schizoaffective psychosis/
(Psychosis or psychotic or schizophreni* or sever* mental ill* or sever*
mental disorder* or psychiatric crisis* or crises*).ti,ab,tw.
12 or 13 or 14 or 15 or 16
3 and 11 and 17

Results: 623
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PsycINFO (Ovid)
1
2

3
4
5
6
7
8
9
10
11
12
13
14

1
2

3
4
5
6
7
8
9
10
11
12

exp Prodrome/
(at risk mental state* or ARMS* or psychosis risk* or psychosis
prediction* or psychosis onset* or prodrom* or prodromal psychosis* or
high risk* or ultra-high risk* or ultra high risk* or UHR or CHR or clinical
high risk* or clinical-high risk* or high clinical risk* or referr* or help
seeking* or progression to first-episode psychosis*).ti,ab,tw.
1 or 2
exp "Costs and Cost Analysis"/
exp Health Care Economics/
(economic evaluation* or health economic* or cost-effectiveness* or costbenefit* or cost analysis*).ti,ab,tw.
4 or 5 or 6
exp Schizophrenia/
exp Psychosis/
exp Affective Psychosis/
exp Schizoaffective Disorder/
(Psychosis or psychotic or schizophreni* or sever* mental ill* or sever*
mental disorder* or psychiatric crisis* or crises*).ti,ab,tw.
8 or 9 or 10 or 11 or 12
3 and 7 and 13

Results: 97

Cochrane
MeSH descriptor: [Prodromal Symptoms] explode all trees
(at risk mental state* or ARMS* or psychosis risk* or psychosis
prediction* or psychosis onset* or prodrom* or prodromal psychosis* or
high risk* or ultra-high risk* or ultra high risk* or UHR or CHR or clinical
high risk* or clinical-high risk* or high clinical risk* or referr* or help
seeking* or progression to first-episode psychosis*):ti,ab,kw
#1 or #2
MeSH descriptor: [Cost-Benefit Analysis] explode all trees
MeSH descriptor: [Costs and Cost Analysis] explode all trees
(economic evaluation* or health economic* or cost-effectiveness* or costbenefit* or cost analysis*):ti,ab,kw
#4 or #5 or #6
MeSH descriptor: [Schizophrenia] explode all trees
MeSH descriptor: [Psychotic Disorders] explode all trees
(Psychosis or psychotic or schizophreni* or sever* mental ill* or sever*
mental disorder* or psychiatric crisis* or crises*):ti,ab,kw
#8 or #9 or #10
#3 and #7 and #11

Results: 566
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Grey Literature Search Strategy
1

1

2
3

4

Dissertations & Theses
noft("at risk mental state" OR "ultra high risk" OR "clinical high risk")

Results: 76

Scopus
TITLE-ABS-KEY ( "at risk mental state*" OR "ARMS*" OR "psychosis
risk*" OR "psychosis prediction*" OR "psychosis onset*" OR
"prodrom*" OR "prodromal psychosis*" OR "high risk*" OR "ultrahigh risk*" OR "ultra high risk*" OR "UHR" OR "CHR" OR "clinical
high risk*" OR "clinical-high risk*" OR "high clinical risk*" OR
"referr*" OR "help seeking*" OR "progression to first-episode
psychosis*" )
TITLE-ABS-KEY ( "economic evaluation*" OR "health economic*" OR
"cost-effectiveness*" OR "cost-benefit*" OR "cost analysis*" )
TITLE-ABS-KEY ( "Psychosis" OR "psychotic" OR "schizophreni*"
OR "sever* mental ill*" OR "sever* mental disorder*" OR "psychiatric
crisis*" OR "crises*" )
#1 AND #2 AND #3

Results: 302
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S.
Helper questions to consider
no.
Relevance
Are the demographics similar?
Are risk factors similar?
Are behaviors similar?
1
Is the medical condition similar?
Are comorbidities similar?
Does the intervention analyzed in the model match the
intervention you are interested in?
2
Have all relevant comparators been considered?
Does the background care in the model match yours?
Are the health outcomes relevant to you considered?
3
Are the economic end points relevant to you
considered?
Is the geographic location similar?
Is the health care system similar?
4
Is the time horizon applicable to your decision?
Is the analytic perspective appropriate to your decision
problem?
Credibility
Validation
Has the model been shown to accurately reproduce what
was observed in the data used to create the model?
1

Has the model been shown to accurately estimate what
actually happened in one or more separate studies?
Has the model been shown to accurately forecast what
eventually happens in reality?

Question

Valmaggia
et al 2009

McCrone
et al 2013

Perez
et al 2015

Wijnen
et al 2019

Yes

No

Yes

No

No

No

No

No

Yes

Yes

No

No

Yes

No

No

Yes

No

No

No

Yes

Is the population relevant?

Are any critical
interventions missing?

Are any relevant outcomes
missing?

Is the context (settings and
circumstances) applicable?

Is external validation of the
model sufficient to make its
results credible for your
decision?

98

2

3

Have the process of internal verification and its results
been documented in detail?
Has the testing been performed systematically?
Does the testing indicate that all the equations are
consistent with their data sources?
Does the testing indicate that the coding has been
correctly implemented?
Does the model contain all the aspects considered
relevant to the decision?
Are all the relevant aspects represented and linked
according to the best understanding of their
characteristics?
Have the best available data sources been used to inform
the various aspects?
Is the time horizon sufficiently long to account for all
relevant aspects of the decision problem?

Is internal verification of the
model sufficient to make its
results credible for your
decision?
No

No

No

Yes

Yes

No

Yes

Yes

Yes

Yes

Yes

Yes

Does the model have
sufficient face validity to
make its results credible for
your decision?

Are the results plausible?
If others have rated the face validity, did they have a
stake in the results?
Design
Was there a clear, written statement of the decision
problem, modeling objective, and scope of the model?

4

Was there a formal process for developing the model
design (e.g. influence diagram, concept map)?
Is the model concept and structure consistent with, and
adequate to address, the decision problem/objective and
the policy context?
Have any assumptions implied by the design of the
model been described, and are they reasonable for your
decision problem?
Is the choice of model type appropriate?
Were key uncertainties in model structure identified and
their implications discussed?

Is the design of the model
adequate for your decision
problem?

99

Data
All things considered, do you agree with the values used
for the inputs?
5
Did the approaches to obtaining and processing the data
inputs meet the criteria from their corresponding
questionnaires?
Analysis

Are the data used in
populating the model
suitable for your decision
problem?
Were the analyses
performed using the model
adequate to inform your
decision problem?
Was there an adequate
assessment of the effects of
uncertainty?

6

7

Yes

Yes

Yes

Yes

No

No

No

Yes

Yes

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

Yes

Yes

Yes

No

No

No

No

Yes

Yes

Yes

Yes

Reporting
Did the report of the analyses provide the results needed
for your decision problem?
Was adequate nontechnical documentation freely
accessible to any interested reader?
8
Was technical documentation, in sufficient detail to
allow (potentially) for replication, made available
openly or under agreements that protect intellectual
property?
Interpretation
9

Was the reporting of the
model adequate to inform
your decision problem?

Was the interpretation of
results fair and balanced?

Conflict of Interest
10
11

Were there any potential
conflicts of interest?
If there were potential
conflicts of interest, were
steps taken to address these?
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Appendix E Consolidated Health Economic Evaluation Reporting Standards (CHEERS)
Section/item
Item Recommendation
no.
Title and Abstract
Title

1

Abstract

2

Introduction
Background
and objectives
Methods
Target
population and
subgroups
Setting and
location
Study
perspective
Comparators

Identify the study as an economic evaluation or use more
specific terms such as ‘‘cost-effectiveness analysis’’, and
describe the interventions compared
Provide a structured summary of objectives, perspective,
setting, methods (including study design and inputs), results
(including base case and uncertainty analyses), and
conclusions

37

3

Provide an explicit statement of the broader context for the
study. Present the study question and its relevance for health
policy or practice decisions

38-39

4

Describe characteristics of the base case population and
subgroups analyzed, including why they were chosen

40-43

5

State relevant aspects of the system(s) in which the
decision(s) need(s) to be made
Describe the perspective of the study and relate this to the
costs being evaluated
Describe the interventions or strategies being compared and
state why they were chosen
State the time horizon(s) over which costs and consequences
are being evaluated and say why appropriate
Report the choice of discount rate(s) used for costs and
outcomes and say why appropriate
Describe what outcomes were used as the measure(s) of
benefit in the evaluation and their relevance for the type of
analysis performed
Single study-based estimates: Describe fully the design
features of the single effectiveness study and why the single
study was a sufficient source of clinical effectiveness data
Synthesis-based estimates: Describe fully the methods used
for identification of included studies and synthesis of clinical
effectiveness data
If applicable, describe the population and methods used to
elicit preferences for outcomes

40-43

Single study-based economic evaluation: Describe
approaches used to estimate resource use associated with the
alternative interventions. Describe primary or secondary
research methods for valuing each resource item in terms of

N/A

6
7

Time horizon

8

Discount rate

9

Choice of
health outcomes

10

Measurement of
effectiveness

11a

11b

Measurement
and valuation of
preferencebased outcomes
Estimating
resources and
costs

Reported
on page
no/line no

12

13a

37

52
40
40
52
52-53

N/A

Appendix
F&G
N/A
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13b

its unit cost. Describe any adjustments made to approximate
to opportunity costs
Model-based economic evaluation: Describe approaches and
data sources used to estimate resource use associated with
model health states. Describe primary or secondary research
methods for valuing each resource item in terms of its unit
cost. Describe any adjustments made to approximate to
opportunity costs
Report the dates of the estimated resource quantities and unit
costs. Describe methods for adjusting estimated unit costs to
the year of reported costs if necessary. Describe methods for
converting costs into a common currency base and the
exchange rate
Describe and give reasons for the specific type of decisionanalytical model used. Providing a figure to show model
structure is strongly recommended
Describe all structural or other assumptions underpinning the
decision-analytical model

Currency, price
date, and
conversion

14

Choice of
model

15

Assumptions

16

Analytical
methods

17

Describe all analytical methods supporting the evaluation.
This could include methods for dealing with skewed,
missing, or censored data; extrapolation methods; methods
for pooling data; approaches to validate or make
adjustments (such as half cycle corrections) to a model; and
methods for handling population heterogeneity and
uncertainty

18

Report the values, ranges, references, and, if used,
probability distributions for all parameters. Report reasons or
sources for distributions used to represent uncertainty where
appropriate. Providing a table to show the input values is
strongly recommended
For each intervention, report mean values for the main
categories of estimated costs and outcomes of interest, as
well as mean differences between the comparator groups. If
applicable, report incremental cost-effectiveness ratios
Single study-based economic evaluation: Describe the
effects of sampling uncertainty for the estimated incremental
cost and incremental effectiveness parameters, together with
the impact of methodological assumptions (such as discount
rate, study perspective)
Model-based economic evaluation: Describe the effects on
the results of uncertainty for all input parameters, and
uncertainty related to the structure of the model and
assumptions
If applicable, report differences in costs, outcomes, or costeffectiveness that can be explained by variations between
subgroups of patients with different baseline characteristics
or other observed variability in effects that are not reducible
by more information

Results
Study
parameters

Incremental
costs and
outcomes

19

Characterizing
uncertainty

20a

20b

Characterizing
heterogeneity

Discussion

21

46-52 &
Appendix
G

46-52 &
Appendix
G

40-42

Figure 3.1
&
Appendix
G
55-56 &
Appendix
G

55-56 &
Appendix
G

56

N/A

56-62

N/A
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Study findings,
limitations,
generalizability,
and current
knowledge
Other
Source of
funding
Conflicts of
interest

22

Summarize key study findings and describe how they
support the conclusions reached. Discuss limitations and the
generalizability of the findings and how the findings fit with
current knowledge

62-67

23

Describe how the study was funded and the role of the
funder in the identification, design, conduct, and reporting of
the analysis. Describe other non-monetary sources of support
Describe any potential for conflict of interest of study
contributors in accordance with journal policy. In the
absence of a journal policy, we recommend authors comply
with International Committee of Medical Journal Editors
recommendations

68

24

68
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Appendix F Focused MEDLINE Search Strategy
Both search strategies were attempted to find parameter values for the decision tree (search strategy 1) and
Markov model (search strategy 2) on 11/5/19 and 11/16/19 respectively. Examining the references of
search results and hand-searching was also completed.
Appendix F Focused MEDLINE Search Strategy
Search Strategy #1 - Medline (Ovid)
1
2

3
4
5
6
7
8
9
10
11

exp Prodromal Symptoms/
(at risk mental state* or ARMS* or psychosis risk* or psychosis
prediction* or psychosis onset* or prodrom* or prodromal psychosis* or
high risk* or ultra-high risk* or ultra high risk* or UHR or CHR or clinical
high risk* or clinical-high risk* or high clinical risk* or referr* or help
seeking* or progression to first-episode psychosis*).ti,ab,tw.
1 or 2
exp Schizophrenia/
exp Psychotic Disorders/
(Psychosis or psychotic or schizophreni* or sever* mental ill* or sever*
mental disorder* or psychiatric crisis* or crises*).ti,ab,tw.
4 or 5 or 6
exp Canada/
(Canada or Canadian or Ontario or London or Quebec or
Montreal).ti,ab,tw.
8 or 9
3 and 7 and 10

Results: 258

Search Strategy #2 - Medline (Ovid)
1
2

3
4
5
6
7
8
9

10
11

12
13

exp Prodromal Symptoms/
(at risk mental state* or ARMS* or psychosis risk* or psychosis
prediction* or psychosis onset* or prodrom* or prodromal psychosis* or
high risk* or ultra-high risk* or ultra high risk* or UHR or CHR or clinical
high risk* or clinical-high risk* or high clinical risk* or referr* or help
seeking* or progression to first-episode psychosis*).ti,ab,tw.
1 or 2
exp Schizophrenia/
exp Psychotic Disorders/
(Psychosis or psychotic or schizophreni* or sever* mental ill* or sever*
mental disorder* or psychiatric crisis* or crises*).ti,ab,tw.
4 or 5 or 6
3 and 7
(first episode psychosis or first-episode psychosis or FEP or first psychotic
episode or first episode of schizophrenia or early onset psychosis or early
onset schizophren* or early psycho* or early schizophren* or early
admission* or first admission*).ti,ab,tw.
exp Canada/
(Canada or Canadian or Ontario or London or Quebec or Montreal or
British Columbia or Alberta or Saskatchewan or Newfoundland or Nova
Scotia).ti,ab,tw.
10 or 11
(8 or 9) and 12

Results: 555
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G.1

Transition Probabilities

The presented transition probabilities in this appendix correspond with the ‘Transition
Number’ in Table 3.1 and Figure 3.1.
G.1.1

Transition Probabilities for Annual Risk Assessment and UHR Treatment

The probabilities to convert to FEP, given treatment for two years, were based on Figure
1 in the original North American Prodrome Longitudinal Study (NAPLS) examining the
NAPLS risk calculator.22 In this publication, UHR participants were treated based on the
standard of care available in each of the eight data collection sites (UHR treatment
centers). They examined the proportion of the sample who converted (converters = 84
people) and did not convert (non-converters = 512 people) in their respective risk
classes.22
The following formula was used to determine probability to convert to FEP, given
treatment for two years in the UHR population:
𝑝(𝐴𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑛𝑣𝑒𝑟𝑡 𝑡𝑜 𝐹𝐸𝑃 | 𝑇𝑟𝑡 (2 𝑦𝑟𝑠))
=

𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑤ℎ𝑜 𝑐𝑜𝑛𝑣𝑒𝑟𝑡𝑒𝑑 𝑖𝑛 𝑟𝑖𝑠𝑘 𝑐𝑎𝑡𝑒𝑔𝑜𝑟𝑦
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑖𝑛 𝑟𝑖𝑠𝑘 𝑐𝑎𝑡𝑒𝑔𝑜𝑟𝑦

Eq. 1

To convert our two-year transition probabilities to one-year transition probabilities, we
used Eq. 2 to convert the two-year transition probabilities to annual rates and Eq. 3 to
convert these rates to one-year transition probabilities. These equations assume that the
events that occur have a constant rate.
− [ln (1 − 𝑝)]
𝑡

Eq. 2

𝑝 = 1 − exp {−𝑟𝑡}

Eq. 3

𝑟 =

where r is the rate, p is the probability, and t is the time period of interest.92
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Using Eq. 1-3, we estimated the one-year transition probability used in the model:
𝑝(𝐴𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑛𝑣𝑒𝑟𝑡 𝑡𝑜 𝐹𝐸𝑃 | 𝑇𝑟𝑡 (2 𝑦𝑟𝑠)) =

𝐴𝑛𝑛𝑢𝑎𝑙 𝑅𝑎𝑡𝑒 = 𝑟 =

27
= 0.070
388

− [ln (1 − 0.070)]
= 0.036
2

𝑝(𝐴𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑛𝑣𝑒𝑟𝑡 𝑡𝑜 𝐹𝐸𝑃 | 𝑇𝑟𝑡 (1 𝑦𝑟)) = 1 − exp {−0.036 × 1} = 0.036

Therefore, the one-year transition probability for a treated UHR individual with a NAPLS
risk score <20% to convert to FEP was about 3.6% (Transition Number 5).
To calculate the estimated probability for conversion to FEP, given no treatment (i.e.
annual risk assessment) for one year in the <20% risk group, we adjusted the probability
for the treated group to convert to psychosis (3.6%) using the relative risk (RR) from a
previous meta-analysis by van der Gaag and collegues.93 The meta-analysis reported a
RR of 0.463 (95% CI = 0.33–0.64) at 12 months to convert to psychosis for those
enrolled in early psychosis intervention (generally medication and cognitive behavioral
therapy) compared to a control condition (generally placebo and monitoring or placebo
and supportive therapy). We used the RR to estimate the risk increase expected if the
treated group was suddenly untreated. Eq. 4 was used below.
𝑝(𝐴𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑛𝑣𝑒𝑟𝑡 𝑡𝑜 𝐹𝐸𝑃 | 𝑁𝑜 𝑇𝑟𝑡, 𝑦𝑟 1) =

𝑝(𝐴𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑛𝑣𝑒𝑟𝑡 𝑡𝑜 𝐹𝐸𝑃 |𝑇𝑟𝑡, 𝑦𝑟 1)
𝑅𝑅 𝑖𝑛 𝑦𝑒𝑎𝑟 1 (𝑇𝑟𝑡 𝑣𝑠. 𝑁𝑜 𝑇𝑟𝑡)

Eq. 4

Using Eq.4:
𝑝(𝐴𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑛𝑣𝑒𝑟𝑡 𝑡𝑜 𝐹𝐸𝑃 | 𝑁𝑜 𝑇𝑟𝑡, 𝑦𝑟 1) =

3.6%
= 7.7%
0.463

Therefore, the one-year transition probability for an untreated UHR individual, given an
annual risk assessment, with a NAPLS risk score <20% to convert to FEP was about
7.7% (Transition Number 2).
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The above equations (Eq. 1 – 3) were also used to calculate the probability for conversion
to FEP, given treatment for one year in the ≥20% risk group (UHR treatment or
Transition Number 3 and 6 = 14.8%). The untreated probability was not calculated for
this risk group because the model called for those at ≥20% risk to be treated with UHR
treatment in both the risk stratification strategy and the standard ‘treat all’ strategy.
Evidence suggests that the risk to convert to FEP reduces over time.90,93 In the second
year of treatment, the probability to convert for the untreated group who were <20% risk
was calculated based on the average between the probability in the third year and the first
year for those under the annual risk assessment strategy using Eq.5 (See Table G.1 for
parameter values).
𝑃(𝐴𝑛𝑛𝑢𝑎𝑙 𝐶𝑜𝑛𝑣𝑒𝑟𝑡 𝑡𝑜 𝐹𝐸𝑃 | 𝑁𝑜 𝑇𝑟𝑡, 𝑦𝑟 2)
=

𝑝(𝐴𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑛𝑣𝑒𝑟𝑡 𝑡𝑜 𝐹𝐸𝑃 |𝑁𝑜 𝑇𝑟𝑡, 𝑦𝑟 1) + 𝑝(𝐴𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑛𝑣𝑒𝑟𝑡 𝑡𝑜 𝐹𝐸𝑃 |𝑁𝑜 𝑇𝑟𝑡, 𝑦𝑟 3)
2

Eq. 5

Using Eq.5:
𝑝(𝐴𝑛𝑛𝑢𝑎𝑙 𝐶𝑜𝑛𝑣𝑒𝑟𝑡 𝑡𝑜 𝐹𝐸𝑃 | 𝑁𝑜 𝑇𝑟𝑡, 𝑦𝑟 2) =

7.7% + 3.6%
= 5.6%
2

Following two years of the UHR treatment or annual risk assessments at a specialized
UHR clinic, UHR patients then received health care from general mental health services
(3+ years). There is no literature available to inform the long-term projection of
conversion risk within an UHR population stratified by NAPLS risk scores (3+ years), so
the probability to convert was assumed and can be seen in the table below for the <20%
risk population (Table G1). The ≥20% risk group was treated regardless of what strategy
they were enrolled in (i.e. Risk stratification strategy or Standard ‘treat all’ strategy). The
risk to convert was assumed to remained steady over the 15 years at 14.8% in this group
(Transition Number 10). The uncertainty around these parameter values were assessed
in comprehensive sensitivity analyses (Table G.5 or Table G.7).
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Table G.1 Probabilities to convert to psychosis for the <20% UHR group
Year

Transition
Number

p(Annual convert to FEP |
No Trt, yr x)

Transition
Number

p(Annual convert to FEP |
Trt, yr x))

1

2

0.077

5

0.036

2

2

0.056

5

0.036

3+

8

0.036

8

0.036

Abbreviations: FEP, First Episode Psychosis; p, probability; RR, Relative Risk; Trt, Treatment; Yr, Year.

G.1.2

Transition Probabilities for Mortality in the FEP and Post-FEP States

Age-dependent mortality probabilities for the general population were derived from
Statistics Canada.95 Since there is evidence to suggest that mortality is higher in those
experiencing psychosis in disorders such as schizophrenia,96 age-specific standardized
mortality ratios (SMR) from an unpublished study on the Ontario FEP population (in
press)100 was used to estimate mortality for those in the psychosis states: FEP and PostFEP states. We multiplied the general population mortality rate by the SMR (Eq. 6) and
converted this to a one-year probability for use in the model.
𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑟𝑎𝑡𝑒 𝑓𝑜𝑟 𝑝𝑠𝑦𝑐ℎ𝑜𝑠𝑖𝑠, 𝑎𝑡 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑒𝑑 𝑎𝑔𝑒 = (𝑔𝑒𝑛𝑒𝑟𝑎𝑙 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑟𝑎𝑡𝑒) × 𝑆𝑀𝑅

Eq. 6

Table G.2 specified the age-dependent SMRs used as the cohort aged over the 15 years.
Table G.2 Standard mortality ratios for the psychosis and post-psychosis states
Age Range

SMR

16-24

10.4

25-29

13.5

30-34

11.9

Abbreviations: SMR, Standard Mortality Ratio.

G.1.3

Transition Probabilities to the ‘Not UHR’ State

The study used was a two-year follow up of people originally enrolled in the NAPLS
study.101 The study found that about 33.5% were symptomatic ("symptomatic but not
currently meeting criteria for a prodromal risk syndrome").101 This value was converted
to a 1-year transition probability using Eq. 2 and Eq. 3 (18.4%). Since there is a paucity
of literature available for outcomes for recovery from the UHR state, we assumed that
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this probability would be used for both the <20% risk state and ≥20% risk state to
transition to the ‘Not UHR’ state (Transition Number 7 and 9). Uncertainty around this
parameter was assessed by extensive sensitivity analyses (Table G.5 or Table G.7).
G.1.4

Transition Probabilities from FEP to Post-FEP or Remission

The focused MEDLINE search strategy returned a study by Jordan and colleagues, which
examined FEP service data in Montreal, Canada over one year.102 We assumed that PostFEP was incomplete remission of positive remission symptoms only, whereas, remission
refers to remission from both positive and negative symptoms and followed the
consensus for remission criteria by Andreason and colleagues.91 The study determined
that 30% of their cohort was in total remission for 12 months, while 67.8% were in
positive remission for about seven months.102 They were used for the transition
probability from the FEP state to the Remission state and Post-FEP state, respectively
(Transition Number 12 and 11, respectively).
G.1.5

Transition Probabilities Between Remission and Post-FEP

The focused MEDLINE search returned no results on Canadian studies with probabilities
to transition from the Remission state to Post-FEP (incomplete remission) or Post-FEP to
Remission. As a result, the values from the original PsyMod model were used
(Transition Number 13 and 14) and the methods on how these were derived are
available elsewhere.81
G.2

Service Use

Service use was predominantly retrieved from the Prodromal Symptoms in Psychosis
Early Clinical Treatment (PROSPECT) clinic. Hospitalization and Emergency
Department (ED) service use for the UHR, FEP, and Post-FEP states were gathered from
two key 2018 Canadian publications from Anderson and colleagues (Table G.3).16,104
Data used to estimate hospitalization and ED use for the UHR group was converted to
annual transition probabilities using Eq. 2 and Eq. 3. Since the data did not stratify
service use by risk class, we operated under the assumption that these adjusted annual
probabilities for ED and hospitalization use represented the higher risk group (≥20%)
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more than the <20% risk group. We assumed the <20% risk group used half the services
of the ≥20% risk group. We also acknowledge that the data used in this study may have
included people who did not meet the UHR criteria – as no UHR clinics existed in this
time to confirm – though they likely displayed prodromal symptoms.104 For the data
collected in literature to determine ED and hospitalization use for the FEP and Post-FEP
states, we assumed that those who had left the program were in incomplete remission
(Post-FEP).16
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Table G.3 Emergency department and hospitalization service use data
State
Source
Assumptions
During UHR Treatment or Annual Risk Assessment
ED visits
UHR treatment reduces
Under UHR treatment, we assume half
service use by 50% (L,
≥20% UHR
the ED use compared to general mental
Palaniyappan, Personal
health services.
Communication)
(i) While receiving annual risk
assessments, we assume the same
amount of ED use as general mental
<20% UHR
Same source as above
health services;
(ii) Under UHR treatment, we assume
half the ED use as general mental health
services
Hospitalizations
Under UHR treatment, we assume half
≥20% UHR
Same source as above
the hospitalizations compared to general
mental health services.
(i) While receiving annual risk
assessments, we assume the same
amount of hospitalizations as general
<20% UHR
Same source as above
mental health services;
(ii) Under UHR treatment, we assume
half the hospitalizations compared to
general mental health services.
Post-UHR Treatment (General Mental Health Services)
ED visits
13.1% in six months
We applied this data to the probability of
≥20% UHR
(Anderson et al,104
ED visits in general mental health
2018)
services
Assumed to be half the ED use of those
<20% UHR
Estimation
at >20% risk
26.2% in two years
FEP
Converted to a one-year probability
(Anderson et al,16 2018)
We took data from the percentage of
22.6% in three years
people out of an FEP program (three
Post-FEP
(Anderson et al,16 2018) years after) who visited the ED and
converted it to a one-year probability
Hospitalizations
7.2% in six months
We applied this data to the probability of
≥20% UHR
(Anderson et al,104
hospitalization in general mental health
2018)
services
Assumed to be half the hospitalization
<20% UHR
Estimation
use of those at >20% risk
26.7% in two years
FEP
Converted to a one-year probability
(Anderson et al,16 2018)
We took data from the percentage of
16.2% in three years
people out of an FEP program (three
Post-FEP
(Anderson et al,16 2018) years after) who were hospitalized and
converted it to a one-year probability
Abbreviations: ED, Emergency Department; FEP, First Episode of Psychosis; UHR, Ultra-High Risk.

Annual
Probability (%)

12.2

(i) 12.2; (ii) 6.1

6.9

(i) 6.9; (ii) 3.5

24.5
12.2
14.1

8.2

13.9
6.9
14.4

5.7
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G.3

Cost Methods

To determine costs used in the model, the following general formula was applied:
𝑇𝑜𝑡𝑎𝑙 𝑐𝑜𝑠𝑡 = 𝑐𝑜𝑠𝑡 𝑝𝑒𝑟 𝑈 × 𝑠𝑒𝑟𝑣𝑖𝑐𝑒 𝑢𝑠𝑒

Eq. 7

Unit costs (cost per U) were derived from the Ontario schedule of benefits (SOB),105 but
these cost per U only applied to physicians (i.e. psychiatrists).
When unit costs were readily available (only for physicians), the following formula
below was used to determine the annual cost to the health system per patient:
𝐴𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑠𝑡 𝑡𝑜 ℎ𝑒𝑎𝑙𝑡ℎ 𝑠𝑦𝑠𝑡𝑒𝑚 𝑝𝑒𝑟 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 (𝑃ℎ𝑦𝑠𝑖𝑐𝑖𝑎𝑛𝑠)
𝑙𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝑒𝑎𝑐ℎ 𝑠𝑒𝑠𝑠𝑖𝑜𝑛
𝑐𝑜𝑠𝑡 𝑝𝑒𝑟 𝑈 × 𝐴𝑛𝑛𝑢𝑎𝑙 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑜𝑓 𝑠𝑒𝑟𝑣𝑖𝑐𝑒 × (
)
𝑈
=
𝑃𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑝𝑒𝑟 𝑠𝑒𝑠𝑠𝑖𝑜𝑛

Eq. 8

where unit (U) = 0.5 hours (as per SOB guidelines).
A sample calculation follows below:
The cost to the health system per patient for repeat consultations with a psychiatrist (see
Table 3.2, Consultations for UHR and FEP Prescriptions) can be calculated using Eq. 8:
From the service use table (Table 3.2), we determined the: (i) Annual frequency of
service (expert opinion from PROSPECT clinic) was 4 consultations per year; (ii) Length
of each session (expert opinion from PROSPECT clinic) was 0.5 hours per session; (iii)
Cost per U or unit cost (SOB code K198) was $86.85 per 0.5 hours for out-patient
psychiatric care; and (iv) Patients per session (expert opinion from PROSPECT clinic)
was 1 patient in consultation with psychiatrist at a time.
𝐴𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑠𝑡 𝑡𝑜 ℎ𝑒𝑎𝑙𝑡ℎ 𝑠𝑦𝑠𝑡𝑒𝑚 𝑝𝑒𝑟 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑓𝑜𝑟 𝑐𝑜𝑛𝑠𝑢𝑙𝑡𝑎𝑡𝑖𝑜𝑛𝑠 𝑤𝑖𝑡ℎ 𝑝𝑠𝑦𝑐ℎ𝑖𝑎𝑡𝑟𝑖𝑠𝑡
=

86.85 × 4 × (
1

0.5
)
0.5 = $347.40
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In situations where unit costs were not available (for services offered by nonphysicians),
methods derived from the 2018 Ontario technology health assessment for cognitive
behavioral therapy for psychosis (pg.58-60) were used to calculate the applied hourly
salary as a proxy for unit costs.106
Applied hourly salary was calculated based on the formula below:
𝐴𝑝𝑝𝑙𝑖𝑒𝑑 ℎ𝑜𝑢𝑟𝑙𝑦 𝑠𝑎𝑙𝑎𝑟𝑦 = 𝒄𝒐𝒔𝒕 𝒑𝒆𝒓 𝑼
=

𝐴𝑛𝑛𝑢𝑎𝑙 𝑠𝑎𝑙𝑎𝑟𝑦
ℎ𝑜𝑢𝑟𝑠
𝑑𝑎𝑦
𝑤𝑒𝑒𝑘𝑠
(7.5
×5
× 52
) ∗ 0.85 𝑎𝑝𝑝𝑙𝑖𝑒𝑑 𝑟𝑎𝑡𝑒
𝑑𝑎𝑦
𝑤𝑒𝑒𝑘
𝑦𝑒𝑎𝑟

Eq. 9

where the applied rate of 85% is the time spent by staff on clinical work, and 1,950 hours
(i.e., 7.5 × 5 × 52) is the number of hours of work per year a full-time employee is
expected to complete.
For example, the cost to the health system per patient for a registered practical nurse
(RPN; annual median salary = $56 000 from the PROSPECT clinic) to perform a UHR
program service was calculated by applying Eq. 9:
𝑐𝑜𝑠𝑡 𝑝𝑒𝑟 𝑈 𝑓𝑜𝑟 𝑅𝑃𝑁 =

56000
= $33.79
ℎ𝑜𝑢𝑟𝑠
𝑑𝑎𝑦
𝑤𝑒𝑒𝑘𝑠
(7.5
×5
× 52
) ∗ 0.85 𝑎𝑝𝑝𝑙𝑖𝑒𝑑 𝑟𝑎𝑡𝑒
𝑑𝑎𝑦
𝑤𝑒𝑒𝑘
𝑦𝑒𝑎𝑟

The above unit cost could then be applied to a modified version of Eq. 8 to determine
annual costs to the health system per patient (Eq. 10):
𝐴𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑠𝑡 𝑡𝑜 ℎ𝑒𝑎𝑙𝑡ℎ 𝑠𝑦𝑠𝑡𝑒𝑚 𝑝𝑒𝑟 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 (𝑛𝑜𝑛 − 𝑝ℎ𝑦𝑠𝑖𝑐𝑖𝑎𝑛𝑠)
=

𝑐𝑜𝑠𝑡 𝑝𝑒𝑟 𝑈 × 𝐴𝑛𝑛𝑢𝑎𝑙 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑜𝑓 𝑠𝑒𝑟𝑣𝑖𝑐𝑒 × 𝑙𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝑒𝑎𝑐ℎ 𝑠𝑒𝑠𝑠𝑖𝑜𝑛
𝑃𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑝𝑒𝑟 𝑠𝑒𝑠𝑠𝑖𝑜𝑛

Eq. 10

Unit costs can be found in the main text (Table 3.2), and additional assumptions for costs
and service use can be found in Table G.4.
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Table G.4 Assumptions for service use and cost of services
Service
NAPLS Assessment
Equipment Cost of NAPLS Calculator
Consultation Using NAPLS Risk
Calculator
Active Case Management
UHR, FEP, and Post-FEP
Case Monitoring
Visits with a Psychiatrist

Psychotherapy (ABC-Coping Skills
Group)
Vocational Support
FEP and Post-FEP
Metabolic Monitoring (Glucose and
Lipid levels)
Pharmacotherapy
UHR and 1/3 of FEP and Post-FEP
Depression Medication – Fluoxetine
40 mg/day
1/2 FEP and Post-FEP
Antipsychotic Medication –
Risperidone 4 mg/day
1/2 FEP
Antipsychotic Injection – Paliperidone
palmitate (Invega Sustenna) 150mg/
month

Assumptions
The NAPLS risk calculator can be freely accessed online and is assumed to cost nothing to access
Fee for general psychiatric consultation (code: A195)

Based on the salary of a registered practical nurse
Fee for out-patient psychiatric care (code: K198). Note that we assume that those in the Post-FEP state
have a less intensive form of case management and do not receive this service. Their case is mostly
managed by their case management nurse
Based on the salary of a psychologist

Based on the salary of a counsellor

Fee for glucose, quantitative or semi-quantitative lab test (code: G002) and the fee for a sputum lab test
for general assessment (for lipids in this case, code: L815)

Cost for generic fluoxetine (Apo-Fluoxetine 20mg Cap, where 1 unit = 1 pill). Patients need to take 2 pills
to meet the 40mg dosage requirement. We assume 1/3 of FEP patients and Post-FEP patients will
continue to receive this medication
Cost for generic Risperidone (Mylan-Risperidone ODT 4mg Orally Disintegrating Tab, where 1 unit = 1
pill). Everyone in Post-FEP receives this, but half of those with FEP will receive antipsychotic injections
instead
Cost of (Paliperidone palmitate) Invega Sustenna 150mg Injection (where 1 unit = 1 injection). Only half
of those with FEP receives this
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Consultations for UHR and FEP Prescriptions
Initial Consultation
Fee for general psychiatric consultation (code: A195)
Repeat Consultation
Fee for out-patient psychiatric care (code: K198)
Injection Nurse (FEP)
Based on the salary of a registered practical nurse
General Mental Health Services
<20% UHR
Pharmacotherapy offered by a GP
Fee for individual primary health care consultation per unit (code: K005)
≥20% UHR
Referral by GP
Fee for individual primary health care consultation per unit (code: K005)
Initial Consultation for
Pharmacotherapy Prescription
Repeat Consultation

Fee for general psychiatric consultation (code: A195)
Fee for out-patient psychiatric care (code: K198)

Not UHR
Initial Consultation

Fee for general psychiatric consultation (code: A195)

Repeat Consultation

Fee for out-patient psychiatric care (code: K198)

Remission
Initial Consultation

Fee for general psychiatric consultation (code: A195)

Repeat Consultation

Fee for out-patient psychiatric care (code: K198)

Abbreviations: ABC, Adversity Belief Consequence; FEP, First Episode Psychosis; GP, General Practitioner; NAPLS, North American Prodrome Longitudinal Study; RPN, Registered Practical Nurse;
SOB, Schedule of Benefits; UHR, Ultra-High Risk.

121

G.4

Utility Modifications and Rank Ordering

There is evidence to suggest that the risk to convert is influenced by prodromal symptom
severity, decline in social functioning, and verbal learning and memory scores.22 As a
result, we assumed that the two UHR risk states would have different utilities. The
original PsyMod model only had one UHR state utility (not stratified by risk=0.640). We
made assumptions about our two UHR risk state utilities (<20% UHR and ≥20% UHR) to
reflect clinical evidence suggesting that outcomes differ between these two risk classes.22
We assumed that the utilities for the <20% risk state was between the ‘no UHR’ state
utility (0.756) and the UHR state utility (0.640) from the original PsyMod model. As a
result, we calculated the average between these two values to derive the <20% state
utility value. We made similar assumptions for the ≥20% risk state utility – we took the
average of the UHR state (0.640) and the FEP state utilities (0.366). Extensive sensitivity
analyses were performed on both these UHR state utilities in order to address the
uncertainty surrounding the true state utility values for both these risk classes (Table G.5
and Table G.9).
< 20% 𝑈𝐻𝑅 𝑠𝑡𝑎𝑡𝑒 𝑢𝑡𝑖𝑙𝑖𝑡𝑦 =

(0.756 + 0.640)
= 0.698
2

≥ 20% 𝑈𝐻𝑅 𝑠𝑡𝑎𝑡𝑒 𝑢𝑡𝑖𝑙𝑖𝑡𝑦 =

(0.640 + 0.366)
= 0.503
2

Rank ordering of the best to the worst outcomes was established for probabilistic
sensitivity analysis (PSA) based on the new utility values and was confirmed by expert
clinical opinion (L Palaniyappan, personal communication):
(𝑃𝑒𝑟𝑓𝑒𝑐𝑡 ℎ𝑒𝑎𝑙𝑡ℎ, 1) > (𝑛𝑜 𝑈𝐻𝑅, 0.756) > (𝑅𝑒𝑚𝑖𝑠𝑠𝑖𝑜𝑛, 0.720) > (< 20% 𝑟𝑖𝑠𝑘, 0.698)
> (≥ 20% 𝑟𝑖𝑠𝑘, 0.503) > (𝑃𝑜𝑠𝑡 − 𝐹𝐸𝑃, 0.490) > (𝐹𝐸𝑃, 0.366) > (𝑑𝑒𝑎𝑡ℎ, 0)

G.5

Methodology for Deterministic Sensitivity Analyses
One-way deterministic sensitivity analysis (DSA) was completed for several

parameters. A one-way DSA changes one value at a time and re-runs the analysis to see
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how the new results differ from the base case result. Table G.5 provides reasons for the
proposed ranges, while Figure G.1 presents the results of the last two DSAs.
Table G.5 Deterministic sensitivity analysis assumptions
Parameter
Description
Cost of the Annual
Risk Assessment

Prevalence of the
≥20% risk state

<20% risk state
utility
≥20% risk state
utility
Post-FEP state
utility

Remission state
utility

Year 2: <20% UHR
State to FEP State
(Annual Risk
Assessment)†
Probability to
transition from the
<20% risk state to
the ‘Not UHR’
state†

Base Case Value

Lower Range
Assumption

Upper Range
Assumption

($66.67 or $216.65)

Estimated unit cost for a
one-hour session with a
trained psychologist
(calculated)106

Unit cost for a one-hour
session with a psychiatrist
based on the Ontario
SOB105

34.9%

From the NAPLS study22

Observations from the
London PROSPECT
clinic (L Palaniyappan,
personal communication)

UHR state utility from
the original PsyMod
publication81

‘No UHR’ state utility
from the original PsyMod
publication81

FEP state utility from the
original PsyMod
publication81

UHR state utility from the
original PsyMod
publication81

Post-FEP state utility
from the original
PsyMod publication81

Estimated UK utility
value for outpatients with
schizophrenia who had
moderate
functioning.108,109

Expert clinical opinion
(L Palaniyappan,
personal
communication)

Remission state utility
from the original PsyMod
publication81

1/3 of the distance
between the year 2 and
year 3 probability

1/3 of the distance
between the year 1 and
year 2 probability

From the NAPLS
study101

From the original PsyMod
publication81

(Range)
$215.65

(34.9% – 57.9%)

0.698
(0.640 – 0.756)
0.503
(0.366 – 0.640)
0.490
(0.362 – 0.490)

0.720
(0720 – 0.756)

5.6%
(4.9% – 6.3%)

18.4%
(18.4% – 44.7%)

Abbreviations: FEP, First Episode Psychosis; PROSPECT, PROdromal Symptoms of Psychosis – Early identifiCation and Treatment;
SOB, Schedule of Benefits; UHR, Ultra-High Risk.
†
The results of these analyses are presented only in Figure G.1.
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We also included a two-way DSA (Figure G.1) that assessed what the base case result
would be in a scenario where both the UHR state utilities remained unchanged from the
value used in the original PsyMod publication (i.e. 0.640).81
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<20% Risk to‘Not UHR’
(18.40% to 44.70%)

B

17,500
15,000
12,500
10,000
18.40 24.98 31.55 38.13 44.70
Probability (%)

ICER ($/QALY)

ICER ($/QALY)

20,000

C

Year 2 Annual Risk
Assessment: <20% UHR to
FEP
(4.9% to 6.3%)

ICER ($/QALY)

A

20000
17500
15000
12500

Changing the UHR State
Utilities
20000
17500
15000
12500
10000
Base Case

10000
4.9

5.25 5.60 5.95
Probability (%)

6.3

Same UHR
Utility Value
(0.640)
Scenario

Figure G.1 Deterministic sensitivity analyses comparing the risk stratification treatment strategy to the standard ‘treat all’ practice
The black bars indicate the base case results, while the grey bars indicate the different ICERs derived from changes made to the: (A) probability to recover from
the UHR state in the <20% UHR group; (B) probability of the <20% UHR group to convert to psychosis in year 2 of the annual risk assessment; and (C) giving
both the <20% UHR state utility and the ≥20% UHR state utility the same value (0.640).
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G.6

Scenario Analysis

The scenario analysis employed different cutoffs for treatment decision in the risk
stratification strategy to see how the cost and effectiveness would change compared to
the standard ‘treat all’ strategy. The effect of the different cutoff strategies were only
reflected in the different transition probabilities for conversion to FEP from the UHR
states. Table G.6 below displays the probabilities to convert to psychosis in the first year
for both the group receiving treatment and not receiving treatment (i.e., annual risk
assessment), but not the second year. The formula remains the same to calculate the
second-year probabilities, as seen in Eq.5.
Table G.6 Probabilities for different treatment cutoffs in the scenario analyses
<n% p(Annual convert
to FEP | Trt, yr 1)

≥n% p(Annual
convert to FEP |

Trt
Cutoff
(n%)†

Proportion
of cohort
≥n‡% risk

<n% p(Annual convert
to FEP | No Trt, yr 1)

10

0.816

0.021

0.010

0.088

15

0.545

0.061

0.028

0.112

20

0.349

0.077

0.036

0.148

25

0.215

0.102

0.047

0.175

30

0.124

0.117

0.054

0.221

35

0.080

0.128

0.059

0.251

40

0.050

0.134

0.062

0.315

45

0.027

0.143

0.066

0.373

50

0.015

0.151

0.070

0.335

55

0.007

0.153

0.071

0.449

60

0.004

0.157

0.073

0.259

65

0.000

0.158

0.073

0.000

Trt or No Trt, yr 1)

Abbreviations: FEP, First Episode Psychosis; p, probability; Trt, Treatment; Yr, Year.
†UHR patients with scores for predicted risk to transition to psychosis under the cutoff receive an annual risk assessment for two
years, while those with scores equal to or greater than the cutoff are treated with UHR treatment for two years. Note that scores are
available up until 64% risk because no UHR patients in Cannon et al 22 scored higher than this value.
‡ n refers to the treatment cutoff value
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G.7

Methodology for the Probabilistic Sensitivity Analyses

For the probabilistic sensitivity analysis (PSA), different distributions were used for the
parameters: Dirichlet distribution, beta distribution, lognormal distribution, and Gamma
distribution. The beta distribution was used often in situations where parameter values
were bound between zero and one (i.e. transition probabilities and utilities), and in
instances where there were only dichotomous transition probability outcomes available
(transition to FEP or remain as UHR).92 For polytomous transitions (in the Markov
model) with multiple possible outcomes available for an individual in any one state, the
Dirichlet distribution was often used.92 Cost uncertainty was represented by the gamma
distribution, since this distribution is appropriate for skewed data – common in cost data
– and is bound between zero and infinity.92 Also, since it is not possible to have negative
costs, the gamma distribution was also the appropriate choice for the cost data. Finally,
the rank ordering for the utility values (see section G.4) was also upheld in all 1000
iterations of the PSA.
With the exception of the Dirichlet distribution alpha and beta values (which are used to
derive one-year transition probabilities for the PSA), Table G.7 displays the alpha and
beta values for two-year transition probabilities. Two-year transition probabilities were
converted to one-year transition probabilities for every iteration in the PSA.
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Table G.7 Distributions for transition probabilities
State
State Transition
Number
Decision Tree
1
Proportion who score
≥20% upon entry into
the UHR clinic
2
Year 1: <20% UHR
State to FEP State
(Annual Risk
Assessment)
3
≥20% UHR State to FEP
State (UHR Treatment)
4
Proportion who score
≥20% upon entry into
the UHR clinic
5
Year 1: <20% UHR
State to FEP State (UHR
Treatment)

Parameter

Distribution

Alpha

Beta

0.349

Beta

208

388

0.077

Lognormal†

N/A

N/A

0.148

Beta

57

151

0.349

Beta

208

388

0.036

Beta

27

361

≥20% UHR State to FEP
State (UHR Treatment)
Markov Model
2
Year 2: <20% UHR
State to FEP State
(Annual Risk
Assessment)
5
Year 2: <20% UHR
State to FEP State (UHR
Treatment)
7
<20% UHR State to Not
UHR State

0.148

Beta

57

151

0.056

Estimate‡

Estimate‡

Estimate‡

0.036

Beta

27

361

0.184

Beta

93

185

0.036

Beta

27

361

0.184

Beta

93

185

0.148

Beta

57

151

0.678

Dirichlet

678

322

0.300

Dirichlet

298

702

0.496

Dirichlet

496

504

0.350

Dirichlet

350

650

6

8

9
10

11
12
13
14

<20% UHR State to FEP
State (General Mental
Health Services)
≥20% UHR State to Not
UHR State
≥20% UHR State to FEP
State (General Mental
Health Services)
FEP State to Post-FEP
State
FEP State to Remission
State
Remission State to PostFEP State
Post-FEP State to
Remission State

Abbreviations: FEP, First Episode Psychosis; N/A, Not Applicable; UHR, Ultra-High Risk.
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†

Uncertainty is assessed by dividing the values retrieved from the beta distribution for the 1-Year probability of treatment for the
treated group by the lognormal distribution for the 1-Year RR.
‡
The distribution is the average between the distribution from Transition Number 2 (Year 1) and Transition Number 2 (Year 3).

Table G.8 shows the one-year alpha and beta values used for the cost data in the PSA.
Table G.8 Distributions for costs
State
Decision Tree
<20% UHR (Annual Risk
Assessment)
≥20% UHR (UHR Treatment)
<20% UHR (UHR Treatment)
≥20% UHR (UHR Treatment)
Markov Model
Not UHR
<20% UHR
≥20% UHR
FEP
Post-FEP
Remission

Cost ($)

Alpha

Beta

952

16

60

3048
2469
2833

16
16
16

191
154
177

389
1046
2095

16
16
16

24
65
131

6880
2662
910

16
16
16

430
166
57

Abbreviations: FEP, First Episode Psychosis; UHR, Ultra-High Risk.

Table G.9 shows the one-year alpha and beta values used for the state utilities in the PSA.
Table G.9 Distributions for state utilities
State
Not UHR
<20% UHR
≥20% UHR

Utility
0.756
0.698
0.503

Alpha
756
698
503

Beta
244
302
497

FEP
Post-FEP
Remission
Death

0.366
0.490
0.720
0

366
490
720
756

634
510
280
244

Abbreviations: FEP, First Episode Psychosis; UHR, Ultra-High Risk.
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